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ABSTRACT 
Antipsychotic drugs (APDs) are used in the treatment of schizophrenia and manic or 
mixed episodes associated with bipolar I disorder. Generally, the so-called atypical 
APDs, such as clozapine, may in contrast to typical APDs improve not only positive, 
but also negative symptoms and some aspects of cognitive impairment associated with 
schizophrenia. However, as also the atypical APDs may be associated with severe side 
effects such as weight gain, dyslipidemia, increased prolactin levels and even 
agranulocytosis, the need for novel and improved pharmacotherapy in this area is 
considerable. This need is underlined by the fact that in recent years, the beneficial 
effects of low doses of atypical APDs in the treatment of depressive symptoms in uni- 
as well as bipolar depression have been increasingly recognized. 
The APD risperidone is one of the most commonly prescribed APDs in the world. In 
similarity with clozapine, risperidone has, however to a smaller extent, affinity for α2-
adrenoceptors, an effect that otherwise distinguishes clozapine from most other APDs. 
We therefore examined if additional α2-adrenoceptor blockade could enhance the 
efficacy of risperidone. The antipsychotic-like effect, extrapyramidal side effect (EPS) 
liability and effects on critical neurotransmitter systems in the brain were studied. Our 
data propose that the α2:D2 ratio by risperidone is indeed not optimal and that its 
antipsychotic-like efficiency can be enhanced by adjunctive treatment with an α2-
adrenoceptor antagonist, e.g. idazoxan, allowing for reduced dosage and a subsequent 
reduced EPS liability, yet with maintained efficacy.  
Asenapine is a recently approved APD with a unique receptor binding profile, 
developed for the treatment of schizophrenia and bipolar disorder. Clinical studies have 
shown that asenapine possesses, in addition to its effect on psychosis and mania, a well 
tolerated side effect profile. Using a range of well established preclinical methods we 
therefore analyzed experimentally the mode of action of asenapine, demonstrating an 
antipsychotic-like activity, low EPS liability and an atypical profile as regards its 
effects on critical neurotransmitter systems in the brain. Notably, asenapine increased 
prefrontal dopamine release and subsequently, via a D1 receptor-mediated mechanism, 
glutamatergic NMDA-induced transmission in the medial prefrontal cortex (mPFC), 
mechanisms implicated in cognitive functioning. Moreover, the release of 
noradrenaline and serotonin was also increased in the mPFC, generally indicating 
antidepressant activity. The profile of asenapine was shown to be similar in several 
important aspects to other potent atypical APDs, e.g. clozapine, which is the most 
efficacious APD presently known, but differs from typical APDs, e.g. haloperidol. It 
was furthermore shown that differential mechanisms are involved in the effects of 
asenapine on subcortical and cortical dopamine regulation. These data indicate that the 
dopamine release in the mPFC may largely depend on an intracortical action. 
Specifically, asenapine in the mPFC was shown to exhibit a pharmacologically 
significant 5-HT2A receptor and α2-adrenoceptor antagonistic activity in vivo, which 
may contribute to the enhanced prefrontal monoamine release.  
In other experiments, the combination of low doses of asenapine and the SSRI 
escitalopram was studied, demonstrating an augmentation of monoaminergic effects of 
escitalopram as well as facilitation of glutamatergic NMDA- and AMPA receptor-
mediated transmission in the mPFC. The results may indicate a mode of action similar 
to that recently proposed to mediate the rapid and potent antidepressant effects of 
ketamine and scopolamine. Collectively, our results support, in principle, the clinical 
utility of adjunctive asenapine in treatment-resistant MDD, and indicate a fast onset of 
action. 
  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Antipsykotiska läkemedel används främst för behandling av schizofreni och 
maniska eller blandade episoder av bipolär sjukdom typ I. Generellt har de så kallade 
atypiska (andra generationens) antipsykotiska läkemedlen, såsom klozapin, till skillnad 
från typiska (första generationen) antipsykotiska läkemedlen visats förbättra inte bara 
positiva utan även negativa symptom och delar av de kognitiva funktionsnedsättningar 
som är vanligen förekommande vid schizofreni. Behandling med atypiska 
antipsykotiska läkemedel kan dock vara associerad med besvärande biverkningar 
såsom viktuppgång, förhöjda blodfetter, ökning av prolaktinnivåer och även 
agranulocytos, vilket gör att behovet av nya och förbättrade behandlingsalternativ inom 
detta terapiområde är stort. På senare tid har man även sett goda effekter av adjuvant 
lågdosbehandling med atypiska antipsykotika i behandlingen av depressiva symptom 
vid både egentlig depression och bipolär sjukdom.  
Asenapin är ett nytt antipsykotiskt läkemedel som är godkänt i Europa för 
behandling av maniska och blandade episoder vid bipolär sjukdom typ I och i USA 
även för behandling av schizofreni. Asenapine har en multireceptorbindningsprofil med 
hög affinitet för t.ex. serotonerga 5-HT2A samt noradrenerga α2 receptorer i relation till 
dopamin D2 receptorer.  
Kortfattat indikerar våra prekliniska resultat att asenapin bör ha en antipsykotisk 
effekt med låg risk för extrapyramidala biverkningar, vilket konfirmerar dess atypiska 
profil. I likhet med andra atypiska, men inte typiska, antipsykotiska läkemedel ökar 
asenapin dopaminfrisättningen markant i prefrontala cortex samt faciliterar glutamaterg 
transmission i pyramidcellerna, vilket sannolikt bidrar till förbättring av negativa 
symptom och kognitiva funktionsnedsättningar. Dessutom har reglermekanismerna för 
den asenapin-inducerade kortikala frisättningen av monoaminer studerats, vilka visat 
sig delvis bero på en lokal blockad av α2-adrenerga och 5-HT2A receptorer i mediala 
prefrontala cortex. Vi har således inter alia visat att asenapin ökar tillgängligheten av 
serotonin och noradrenalin i cortex, vilket kan bidra till dess effekt på depressiva 
symptom. För att ytterligare studera asenapins effekt vid behandling av depressiva 
symptom kombinerades asenapin med det välkända antidepressiva läkemedlet 
escitalopram, vilket visade på en aktivering av frisättningen av monoaminer i 
prefrontala cortex, liksom faciliteringen av glutamaterg NMDA och AMPA 
receptormedierad transmission i pyramidalceller i prefrontala cortex. Sammantaget kan 
dessa resultat förklara att asenapin har effekt på både negativa, kognitiva och 
depressiva symptom samt, i kombination med escitalopram, en verkningsmekanism 
som liknar den som anses mediera den potenta och snabbt insättande antidepressiva 
effekten av ketamin och scopolamin. 
Risperidon är ett av världens mest använda antipsykotiska läkemedel. Våra nya data 
talar för att genom ytterligare blockad av α2-receptorer kan en dosreducering av 
risperidon möjliggöras med bevarad effektstorlek men minskad risk för EPS. Däremot 
sågs ingen förstärkning av den antipsykotiska effekten vid förstärkt 5-HT2A 
receptorblockad. 
Sammantaget synes dessa studier ge en fördjupad preklinisk rational för en rad 
kliniska resultat och observationer gällande ett nytt psykofarmakologiskt läkemedel, 
asenapine, med potentiell användning vid flera psykiatriska sjukdomar, såsom 
schizofreni, bipolär sjukdom och egentlig depression. 
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1 INTRODUCTION 
1.1 Antipsychotic drugs 
 The first antipsychotic drug (APD) chlorpromazine, developed in the early 1950s, 
was discovered in the search for novel antihistaminic drugs but was soon found to be 
effective on psychotic patients (Delay et al., 1952; Laborit and Huguenard, 1951). It 
was thereby groundbreaking and replaced the at the time available treatment options, 
which for example included general sedation, insulin coma and surgical lobotomy 
(Ban, 2001; Black, 1982). Chlorpromazine has a multireceptor binding profile with 
high affinity for e.g. dopaminergic and histaminergic receptors. Soon after, haloperidol 
was synthesized, possessing high D2 receptor affinity and a potent antipsychotic effect 
(Janssen et al., 1958; Leucht et al., 2009). Drugs such as chlorpromazine and 
haloperidol were entitled neuroleptics and are now also called typical or first generation 
APDs.  
The above mentioned clinical observations stimulated basic scientists to explore the 
potential mechanism of action involved. In the 1950s, Carlsson and associates first 
showed that dopamine is a neurotransmitter in its own right and not only a precursor to 
noradrenaline (Carlsson et al., 1957, 1958). Soon after, they also discovered that APDs 
increased dopamine and noradrenaline metabolism, suggesting a compensatory 
activation due to catecholamine receptor blockage (Carlsson and Lindqvist, 1963). The 
antipsychotic action was subsequently shown to correlate with dopamine D2 receptor 
binding in the brain (Creese et al., 1975, 1976; Seeman et al., 1976). 
Even if chlorpromazine and haloperidol were associated with remarkable symptom 
relief, they were found to induce a wide array of side-effects from both the central and 
the peripheral nervous system (see e.g. Kahn et al., 2008). These include 
extrapyramidal symptoms (EPS), such as akathisia (inner restlessness), acute dystonia 
(involuntary sustained muscle contractions), parkinsonism (tremor, hypokinesia and 
rigidity) and tardive dyskinesia (involuntary movements of e.g. the tongue, lips, face 
and extremities). EPS were at that time even considered as a therapeutic marker for 
APDs, i.e. no separation between therapeutic action and side effects was acknowledged 
(Hippius, 1989). In addition to EPS, increased prolactin levels is a common side effect 
of many APDs which may lead to amenorrhea and galactorrhea in women, 
gynecomastia in men and sexual dysfunction in both genders. Since these issues often 
are reason for noncompliance or termination of medication by patients, reduction of 
side effects is of importance to avoid relapses.  
Clozapine is the prototype for atypical APD and a chemical analogue to tricyclic 
antidepressant drugs (TCAs), such as imipramine, although with a potent antipsychotic 
effect, yet with very low EPS liability (Davis et al., 2003; Gross and Langner, 1966; 
Leucht et al., 2009). The atypicality of clozapine refers to the prior definition of APDs, 
where the antipsychotic effect was closely linked to EPS. Although clozapine has a 
very low EPS liability, it may generate substantial weight gain, sedation as well as 
agranulocytosis (Idänpään-Heikkilä et al., 1977). The latter observation led to the 
withdrawal of clozapine from the market, with the exception of some strictly 
hematologically monitored patients responding well to the treatment. In 1990 clozapine 
was re-introduced, since studies had shown its effectiveness in otherwise treatment-
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resistant patients with schizophrenia (Kane et al., 1988; Lindström, 1988; see also 
Lewis et al., 2006). In addition, clozapine has been shown to substantially reduce the 
risk of suicide (see Hennen and Baldessarini, 2005; Meltzer et al., 2003a) and relief of 
negative symptoms and some aspects of cognitive impairment that mostly is associated 
with schizophrenia (Leucht et al., 2009; Meltzer and McGurk, 1999). However, the risk 
of agranulocytosis still reduces its use. 
As a common denominator, all presently available APDs share the ability to block 
dopamine D2 receptors. Studies using the positron emission tomography (PET) 
technique have revealed that, whereas most APDs, including haloperidol, requires 
approximately 70% D2 receptor occupancy to yield adequate clinical effect, an 
increased EPS risk emerges at approximately 80%, indicating a rather narrow 
therapeutic window (Farde et al., 1988), a conclusion that has been supported by 
subsequent preclinical studies (Wadenberg et al., 2000, 2001b). In contrast, clozapine 
generates only approximately 45% D2 receptor occupancy in striatal tissue at clinically 
effective dosage (Farde and Nordström, 1992), and the low dopamine D2 receptor 
occupancy largely explains its very low EPS liability. Apart from moderate blockage of 
D2-like receptors, the superior clinical efficacy of clozapine has been attributed to its 
antagonistic action at serotonergic receptors, in particular 5-HT2A/2C receptors (Ashby 
and Wang, 1996; Meltzer et al., 1989, 2003b; Schotte et al., 1996), although most 
atypical APDs share this effect of clozapine. However, in contrast to other atypical and 
typical APDs but in similarity with antidepressant drugs such as mianserin and 
mirtazapine, clozapine is a highly potent α2-adrenoceptors antagonist, an effect 
suggested to largely explain its unique efficacy (de Boer, 1996; Hertel et al., 1999a; 
Nutt, 1994; Schotte et al., 1996). Moreover, clozapine has been found to act as a partial 
agonist at D1 and 5-HT1A receptors (Newman-Tancredi et al., 1996; Salmi et al., 
1994a), indicating that also other receptors may contribute to its clinical profile (see e.g. 
Svensson, 2003b). In the search for novel improved psychopharmacological agents, the 
group of atypical APDs, also denoted second generation APDs, has successively 
expanded. Thus, several APDs have been developed, some of which with the 
multireceptor binding profile of clozapine in mind, including a high 5-HT2A:D2 binding 
affinity ratio, e.g. risperidone, olanzapine, quetiapine, ziprasidone and most recently 
asenapine (formerly known as Org 5222; Bymaster et al., 1996; Schotte et al., 1996; 
Shahid et al., 2009). 
Preclinical studies have shown that atypical, such as clozapine, but not typical 
APDs, such as haloperidol, markedly augment prefrontal dopamine release (Kuroki et 
al., 1999; Moghaddam and Bunney, 1990; Nomikos et al., 1994). In addition, atypical, 
in contrast to typical, APDs increase the glutamatergic N-methyl-D-aspartate (NMDA)-
induced currents in pyramidal cells of the medial prefrontal cortex (mPFC; Ninan et al., 
2003a). Moreover, prefrontal dopamine may secondarily, via D1 receptors, regulate 
glutamatergic NMDA receptor-mediated transmission (Chen et al., 2004; Goldman-
Rakic et al., 2000; Ninan and Wang, 2003). Previous studies have shown that prefrontal 
dopamine regulation is critically involved in cognition, e.g. working memory, and that 
dysfunctional D1 receptors may contribute to cognitive impairment in schizophrenia 
(Castner and Williams, 2007; Sawaguchi and Goldman-Rakic, 1991). In subcortical 
areas, atypical but not typical APDs augment dopamine release preferentially in the 
shell compared to core subregion of the nucleus accumbens (NAc; Marcus et al., 1996, 
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2000), indicating a more prominent mesolimbic than striatal interaction. These findings 
are supported by studies of regional c-fos expression, comparing the effects in the core 
and shell subregions of typical vs. atypical APDs (Deutch et al., 1992; Robertson and 
Fibiger, 1992). The purported beneficial effects on negative symptoms and cognitive 
impairments by atypical APDs (Meltzer and McGurk, 1999; Riedel et al., 2010) have 
thus been proposed to be related to a preferential mesocorticolimbic selectivity. 
The atypical, or sometimes called third generation, APD, aripiprazole differs from 
the forementioned APDs by being a partial agonist at D2 receptors, indicating a 
“stabilizing”, rather than blocking, effect on dopamine transmission in the brain (Keck 
and McElroy, 2003). In addition, it is a partial agonist at 5-HT1A receptors and an 
antagonist at 5-HT2A/2C receptors. As a result aripiprazole generates less D2 receptor-
associated side effects such as EPS and prolactin increase, as well as very little, if any, 
weight gain (Kane et al., 2002).  
Current limitations of APDs, typical as well as atypical, concern foremost lack of 
treatment efficiency and various side effects (Lieberman et al., 2005), leading to a 
high degree of discontinuation of the medication. Therefore, the need for improved 
pharmacological treatment options is substantial. Even though atypical APDs have 
more favorable tolerability in some aspects, especially concerning a lower risk of 
EPS, there is still a considerable risk of side effects such as weight gain, sedation, 
increased prolactin levels and altered glucose as well as lipid metabolism which may 
lead to diabetes and cardiovascular diseases. However, treatment with APDs 
compared with no treatment has indeed been shown to be associated with a reduced 
mortality in patients with schizophrenia (Tiihonen et al., 2009, 2012). In addition, 
since the degree of cognitive impairment is considered to determine treatment 
outcome in schizophrenia as well as bipolar disorder and major depressive disorder 
(MDD; Atre-Vaidya et al., 1998; Green, 1996; Martinez-Aràn et al., 2004; McCall and 
Dunn, 2003) APDs should ideally improve also cognitive deficits.  
For all these reasons, novel and improved pharmacological strategies to treat 
severe mental disorders are highly needed. This goal may be achieved in several 
ways, including both novel drugs as well as combinations of drugs with 
complementary modes of action both as regards their neurobiological effects in the 
brain and effects on various symptom clusters within the respective disease entities. 
APDs are primarily used in the treatment of schizophrenia and manic or mixed 
episodes associated with bipolar I disorder. In addition, APDs are also used in the case 
of psychosis related to substance abuse and side effects of treatment of Parkinson’s 
disease. In recent years, the beneficial effects of low doses of atypical APDs in the 
treatment of depressive symptoms in uni- as well as bipolar depression have been 
increasingly supported (Chen et al., 2011; Croxtall and Scott, 2010; Debattista and 
Hawkins, 2009; Hardoy and Carta, 2010; Komossa et al., 2010; Montgomery, 2008; 
Nelson and Papakostas, 2009; Thase, 2002; Tohen et al., 2010). This is not surprising 
since schizophrenia and mood disorders have partly overlapping symptomatology 
(psychosis, depressive symptoms and cognitive impairment) and co-morbidities (e.g. 
substance abuse and anxiety). In addition, the etiology and gene susceptibility (see e.g., 
Blackwood et al., 2007; Lichtenstein et al., 2009; Murray et al., 2004) as well as certain 
aspects of dysregulation of monoaminergic transmission (see e.g., Dunlop and 
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Nemeroff, 2007; Meltzer and Huang, 2008; Schildkraut, 1965; Wong et al., 2010), are 
also partly shared. Furthermore, adjunct treatment with APDs can improve the efficacy 
of antidepressant drugs and vice versa (see e.g. Debattista and Hawkins, 2009; Silver et 
al., 2004; Yatham et al., 2005).  
 
1.2 Schizophrenia  
Schizophrenia is a devastating, poorly understood and insufficiently treated 
psychiatric disorder, with a life time prevalence of approximately 1% (Carpenter and 
Buchanan, 1994; Perälä et al., 2007). The onset of schizophrenia often begins in 
adolescence or early adult life, somewhat earlier in men than women (see e.g. Häfner, 
2003), and tends to have a chronic course. The life expectancy of schizophrenic 
patients is reduced due to increased risk of somatic illnesses such as cardiovascular 
disease but also to a considerably increased risk of suicide (Casey et al., 2011; Miles, 
1977; Palmer et al., 2005; Sim et al., 2006).  
1.2.1 Symptomatology 
The onset of schizophrenia is usually preceded by a prodromal phase, where 
depressive and negative symptoms are the most common psychiatric problems, which 
can last for more than a year (see e.g. Häfner et al., 2005). Furthermore, pre-
schizophrenic children have been found to manifest cognitive and neuromotor 
impairments (Jones et al., 1994). The disease can be manifested in different ways and 
the core symptoms are often divided into the three clusters, namely positive, negative 
and cognitive symptoms according to the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV; APA, 2000) or the International Classification of Diseases (ICD-
10; WHO, 1992). Positive symptoms, also referred to as psychotic symptoms, include 
episodic abnormal experiences and behaviors e.g. bizarre or paranoid delusions, 
auditory hallucinations and disorganized speech or thoughts. Negative symptoms 
include e.g. inability to experience pleasure (anhedonia), social withdrawal, apathy and 
poverty of speech (alogia), which can be very disabling. Cognitive impairment is 
manifested by e.g. impaired attention, executive functioning, learning and working 
memory. While psychotic symptoms are of a phasic character, with symptom intensity 
fluctuating over time, negative and cognitive symptoms are of a more stable nature, 
resulting in reduced quality of life, ability to work and social network. Furthermore, 
schizophrenic patients have an increased risk of psychiatric co-morbidity such as 
depression, anxiety and substanse abuse, which is associated with worse outcome 
(Buckley et al., 2009; Sim et al., 2006).  
1.2.2 Etiology and risk factors 
Even though the etiology of schizophrenia is multifactorial and remains poorly 
understood, the underlying pathophysiology most certainly involves both genetic and 
environmental factors. A high degree of heritability has been shown in schizophrenia 
using twin, family and adoptions studies indicating a strong genetic involvement 
(Cannon et al., 2003; Farmer et al., 1987; Lichtenstein et al., 2009). Several 
susceptibility genes have been associated with schizophrenia, thought to be involved in 
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neurotransmission and synaptic function, e.g. dysbindin, neuregulin, Disc1 and the Val 
allele of catechol-O-methyltransferase (COMT; Blackwood et al., 2001; Egan et al., 
2001; Harrison and Weinberger, 2005; Weinberger et al., 2001). However, no single 
gene seems to be responsible, rather a complex interaction between genes and 
environmental factors seem more likely. Exposure to risk factors early in life when the 
brain still is vulnerable and immature may lead to developmental disturbances and, 
subsequently, schizophrenia. Such risk factors include intrauterine infections (Brown et 
al., 2004; Buka et al., 2008; Mortenssen et al., 2007), obstetric complications (Cannon 
et al., 2002), migration (Harrison et al., 1988), urban social living (van Os et al., 2004) 
as well as cannabis abuse (Andréasson et al., 1987). The hypothesis that schizophrenia 
is caused by impaired neurodevelopment, is also supported by genetic studies as well as 
anatomical studies of patients with schizophrenia using brain imaging techniques (see 
Murray et al., 2004). A consistent finding is the frequently reported volume reduction 
of hippocampus and amygdala in schizophrenic patients (Watson et al., 2012) believed 
to be related to impaired cognitive and emotional processing, respectively. Other 
structural neuroanatomical changes in schizophrenia include enlargement of the lateral 
and third ventricles (Morgan et al., 2007). 
1.2.3 The dopamine hypothesis of schizophrenia  
The pathophysiology of schizophrenia is most probably multifactorial (see above) 
and the symptoms of schizophrenia are thought to result from the dysfunction of 
several neurotransmitter systems, among them the dopamine system having received 
most attention. The classical dopamine hypothesis assumes schizophrenia to be due to a 
general upregulation of dopamine transmission in the brain (Carlsson, 1978). This 
notion was originally based on indirect pharmacological evidence demonstrating that 
all clinically effective APDs block D2 receptors (see section 1.1). A hyperdopaminergic 
state was also indirectly supported by the finding that the dopamine precursor L-
dihydroxyphenylalanine (L-DOPA) can induce psychotic-like side effects in the 
treatment of Parkinson’s disease and exaggerate positive symptoms in schizophrenia 
(Angrist et al., 1974; Jenkins and Groh, 1970). In addition, drugs stimulating dopamine 
release, such as amphetamine, usually worsen psychosis in schizophrenic patients 
(Snyder, 1973) and can even induce a psychotic-like state in healthy individuals, effects 
that in turn can be reversed by APDs (Angrist et al., 1974; Brady et al., 1991; 
Lieberman et al., 1987). However, postmortem studies showing e.g. increased levels of 
dopamine or D2 receptors in the brain have been inconclusive since inter alia APDs 
may up-regulate D2 receptors (for review see Davis et al., 1991; Guillin et al., 2007). 
More recently, the development of brain imaging techniques has enabled studies in 
patients, yielding more direct clinical evidence indicating an augmented presynaptic 
synthesis of dopamine in the striatum (STR; Abi-Dargham et al., 2009; Hietala et al., 
1995; Lindström et al., 1999). In addition, an increased striatal dopamine release has 
been demonstrated in schizophrenic patients, that was found to be associated with 
psychotic episodes (Abi-Dargham et al., 1998; Breier et al., 1997; Laruelle et al., 1996). 
These findings support a prominent role of D2 receptor blockage by APDs for the 
improvement of positive symptoms. However, even if typical APDs such as 
haloperidol may improve positive symptoms, the negative and cognitive symptoms of 
schizophrenia are usually more treatment-resistant and may even be exacerbated 
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(Carpenter, 1996). Furthermore, amphetamine has been shown to ameliorate certain 
aspects of negative symptoms associated with schizophrenia (Angrist et al., 1982; 
Goldberg et al., 1991; van Kammen and Boronow, 1988). Already in the seventies, a 
reduced blood flow and a hypofunction of the PFC of schizophrenic patients was 
observed (Andreasen et al., 1992; Berman and Weinberger, 1990; Ingvar and Franzén, 
1974) correlating to cognitive deficits and negative symptoms (da Silva Alves et al., 
2008; Driesen et al., 2008; Tan et al., 2007). Moreover, low levels of dopamine in the 
PFC have been proposed to underlie negative symptoms and impaired cognitive 
functioning, especially regarding working memory, in schizophrenia (Abi-Dargham, 
2011; Goldman-Rakic et al., 2004; Karoum et al., 1987). As mentioned previously, the 
superiority of clozapine in improving negative and cognitive functions in schizophrenia 
has been associated with the ability to enhance prefrontal dopamine outflow (se section 
1.1). These effects are suggested to be mediated via D1 receptors in the prefrontal 
cortex (PFC; Goldman-Rakic et al., 2004). Furthermore, the Val allele of the dopamine 
metabolizing enzyme COMT, leading to increased dopamine catabolism in the PFC, is 
more common in families afflicted by schizophrenia (Egan et al., 2001; Weinberger et 
al., 2001). Specifically, this COMT polymorphism predicts cognitive deficits and 
indicates an impaired prefrontal dopaminergic transmission in patients with 
schizophrenia. Therefore, a modified dopamine dysregulation hypothesis of 
schizophrenia has now been generally accepted, where the psychotic symptoms are 
thought to be associated with hyperactivity or hyperreactivity of the dopamine 
projection to ventral parts of the STR and, at the same time, cognitive and negative 
symptoms may be related to a hypofunctioning dopaminergic neurotransmission in the 
PFC. Consequently, a stabilization of the dopaminergic mesocorticolimbic systems, 
rather than a general blockage of dopamine transmission, would be preferred (see 
Svensson, 2003b). 
1.2.4 The glutamate hypothesis of schizophrenia  
A hypofunction of glutamatergic transmission, e.g. in the PFC, has also been 
proposed to be part of the pathophysiology of schizophrenia (see e.g. Javitt, 2010). This 
hypothesis was originally based on the observation that drugs inhibiting glutamatergic 
neurotransmission via blockage of the N-methyl-D-aspartat (NMDA) receptor, such as 
phencyclidine (PCP), can produce schizophrenia-like symptoms even in healthy 
individuals (Luby et al., 1959). These drugs were also found to aggravate existing 
schizophrenic symptoms in patients, including positive and negative as well as 
cognitive impairments (Javitt and Zukin, 1991; Jentsch and Roth, 1999; Luby et al., 
1959). 
Preclinical studies have shown that selective NMDA receptor blockage generates 
severe behavioral and cognitive abnormalities, including impaired working memory 
(Castner and Williams, 2007; Marcus et al., 2005). In further support of this notion, a 
mouse model expressing only 5% of normal levels of one of the essential NMDA 
receptor (NR1) subunits displayed severe behavioral abnormalities, similar to those 
observed in other animal models of schizophrenia, that could be improved when 
treated with APDs (Mohn et al., 1999). Clinical data have subsequently shown a 
significantly reduced phosphorylation of the NR1 subunit in the PFC and 
hippocampus (Emamian et al., 2004), and postmortem studies have demonstrated 
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impaired expression of several NMDA receptor subtypes in the PFC of schizophrenic 
patients as well as in bipolar disorder and MDD (Beneyto and Meador-Woodruff, 
2008). Taken together, these data strongly support an involvement of NMDA-
receptor dysfunction in the pathophysiology of schizophrenia. 
As mentioned previously, prefrontal dopamine, acting via a D1 receptor-mediated 
mechanism, is considered important for cognitive functioning. There is also in vitro 
evidence suggesting that stimulation of D1 receptors in the PFC augments NMDA 
receptor-mediated transmission (Chen et al., 2004). These mechanisms have been 
suggested to be critically involved in cognitive functioning (Castner and Williams, 
2007; Goldman-Rakic et al., 2004). Indeed, previous preclinical work has shown that 
atypical APDs markedly enhances cortical NMDA receptor-mediated transmission 
and also can reverse cognitive impairments induced by NMDA receptor antagonists, 
an effect mediated via D1 receptors (Chen and Yang, 2002; Jardemark et al., 2010; 
Ninan and Wang, 2003; Snigdha et al., 2011).  
Furthermore, novel leads indicating a clinical antipsychotic effect of e.g. 
mGluR2/3 agonists, regulating the glutamatergic transmission in the brain, support 
the glutamatergic involvement in schizophrenia (Mezler et al., 2010; Patil et al., 
2007). 
Thus, there may be a hypofunctioning of both dopaminergic and glutamatergic 
transmission in the mPFC, while at the same time there seems to be a dopaminergic 
hyperresponsiveness in ventral parts of the STR, leading to psychotic symptoms.  
1.2.5 Serotonergic transmission in schizophrenia 
The involvement of serotonin in the pathophysiology of schizophrenia originally 
emerged from the finding that the psychotomimetic drug lysergic acid diethylamine 
(LSD) interacts with serotonergic receptors (Gaddum and Hameed, 1954; Woolley 
and Shaw, 1957). The mental symptoms generated by LSD may include a psychotic 
state including even paranoia and formal thought disorder as well as negative 
symptoms such as social withdrawal (see Breier, 1995; Rinkel et al., 1955). However, 
the most prominent symptom generated by LSD, visual hallucinations, are rarely 
present in schizophrenia. LSD was later shown to stimulate 5-HT2A receptors. This, in 
turn, was the fundamental reason why most atypical APDs, in particular risperidone, 
were designed to exert high 5-HT2A receptor blocking properties (see section 1.1). 
Since atypical, in contrast to typical, APDs may have better effect on negative 
symptoms and some aspects of cognitive impairment (see section 1.2.7), an 
involvement of the serotonin system and the 5-HT2A receptors in negative and 
cognitive symptoms have been proposed (see e.g. Breier, 1995; Meltzer et al., 2003b). 
Originally, adjunct treatment with the 5-HT2A/2C receptor antagonist ritanserin was 
found to augment the effects of typical APDs, such as haloperidol, in schizophrenic 
patients, in particular with regard to anergia, dysphoria, and negative symptoms, as 
well as antagonism of parkinsonism (Gelders, 1989; Gelders et al., 1986; Reyntjens et 
al., 1986). These clinical effects were subsequently paralleled by preclinical studies 
demonstrating increased prefrontal dopamine availability by adding a 5-HT2A 
receptor blocking agent to D2 antagonists, such as raclopride and haloperidol, and an 
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enhanced antipsychotic-like effect (Andersson et al., 1995; Ichikawa et al., 2001b; 
Westerink et al., 2001). In addition, the dopamine and noradrenaline release in the 
mPFC by clozapine has been shown to be blocked by simultaneous administration of 
a 5-HT2A receptor agonist (Ichikawa et al., 2001a). Although the mechanism is not 
fully understood, antagonism at the 5-HT2A receptor together with D2 receptor 
blockade have been found to interact with a 5-HT1A receptor-mediated mechanism to 
enhance cortical catecholamine output (Ichikawa et al., 2001b). Moreover, clinical 
studies demonstrate augmentation of the effect on negative symptoms using selective 
serotonin re-uptake inhibitors (SSRIs) as add-on to APDs (Silver, 2004). 
1.2.6 Noradrenergic transmission in schizophrenia 
Dysfunctional noradrenergic neurotransmitter systems may also contribute to the 
symptoms of schizophrenia (Yamamoto and Hornykiewicz, 2004). The atypical APD 
clozapine, as well as asenapine and risperidone (although to a lower extent), have all 
affinity for α2-adrenoceptors (Ashby and Wang, 1996; Schotte et al., 1996; Shahid et 
al., 2009). This receptor binding profile has been shown to be importantly involved in 
their clinical action (see section 1.1 and 1.2.7). Indeed, α2-adrenoceptors are known to 
regulate the release of several monoamines, i.e. dopamine, noradrenaline and serotonin, 
and, in addition, the firing activity of these cells (Devoto et al., 2004; Gobert et al., 
1998; Hertel et al., 1999b; Svensson et al., 1975; Wang et al., 2011; see also section 
1.5.4). Clinically, α2-adrenoceptor receptor antagonists have been shown to enhance the 
effect of typical APDs in treatment-resistant schizophrenia (Hecht and Landy, 2012; 
Litman et al., 1996). These clinical findings are supported by preclinical studies 
demonstrating that additional blockade of α2-adrenoceptors enhances the antipsychotic-
like effect of low doses of raclopride, a selective D2 receptor antagonist, as well as 
APDs with low α2-adrenoceptor affinity, i.e. haloperidol and olanzapine, and at the 
same time increases prefrontal dopamine release and stimulates cortical NMDA 
receptor-mediated transmission via D1 receptor activation (Hertel et al., 1999a; Marcus 
et al., 2005; Wadenberg et al., 2007). 
1.2.7 APDs in the pharmacotherapy of schizophrenia  
Treatment of schizophrenia is primarily focused on suppression of symptoms and 
prevention of relapse as well as functional rehabilitation. The therapy is primarily 
based on pharmacological treatment with APDs but includes also psychosocial 
interventions such as cognitive, family and group therapy. In addition, the 
management of possible co-morbidity such as depression, somatic diseases and 
prevention of drug abuse is crucial. Although typical as well as atypical APDs can 
produce full remission of positive symptoms in schizophrenia (Leucht et al., 2009), a 
substantial proportion of patients are still treatment-resistant (Kane et al., 1988, 
2011). However, atypical APDs, such as clozapine, have shown better effect on 
negative symptoms as well as some aspects of cognitive impairment, in comparison 
with typical APDs (Leucht et al., 2009; Meltzer and McGurk, 1999; Riedel et al., 
2010), which is important, as improvement of cognitive impairment is critical for 
treatment outcome (Green, 1996).  
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Since a substantial part of the schizophrenic patients are also afflicted by depression 
(Buckley et al., 2009), a common drug combination is co-treatment with antidepressant 
drugs, such as SSRIs and mirtazapine, added to APDs. Depressive symptoms are a 
major cause for suicidality in schizophrenia, as well as bipolar disorder and MDD. 
Interestingly, modest doses of antidepressant drugs have also been found to enhance the 
efficacy of APDs and may also for this reason be used as adjunctive treatment in 
schizophrenia (Berk et al., 2001; Grinshpoon et al., 2000; Joffe et al., 2009; Kasckow et 
al., 2001; Mizuki et al., 1990, 1992; Poyurovsky et al., 1999, 2003; Shiloh et al., 2002; 
Silver, 1994; Spina et al., 1994; Stenberg et al., 2010; Terevnikov et al., 2011), and, 
most significantly, may dramatically reduce the risk of suicide (Tiihonen et al., 2012).  
Schizophrenia is most often of a chronic character and the neuropsychiatric 
treatment lifelong. Therefore, to avoid relapse, reduction of side effects is of 
importance for compliance to the long-term treatment. Even though long-term 
treatment with APDs is associated with risk of developing severe side effects such as 
EPS, weight gain, sedation and metabolic side effects (see section 1.1), it is 
associated with substantially reduced mortality compared with no antipsychotic use 
(Tiihonen et al., 2009, 2012). 
Against the above mentioned findings and considerations, novel pharmacologic 
treatment options that may reduce also depressive symptoms in schizophrenia are 
indeed needed. 
 
1.3 Bipolar disorder 
Bipolar disorder, also known as manic-depressive disorder, is a severe psychiatric 
mood disorder with approximately 1-2% afflicted (Merikangas et al., 2007, 2011). The 
onset is usually in late adolescence or early adult life and the illness tends to have a 
chronic progress. Men and women are equally affected. The life expectancy is reduced 
for patients with bipolar disorder due to a higher mortality from both somatic illnesses 
(twice as high) as well as due to a high risk of suicide (15 and 22 times increased for 
men and women, respectively; Ösby et al., 2001).  
1.3.1 Symptomatology 
Bipolar disorder is associated with recurrent episodes of hyperactivity and episodes 
of depressive symptoms (APA, 2000; WHO, 1992). Between these episodes, a neutral 
(euthymic) mood reappears. Mixed episodes, in which features of both hyperactivity 
and depression are present at the same time, may also occur as well as rapid cycling, 
i.e. four or more episodes per year. In general the depressive symptoms are 
predominantly expressed (Judd et al., 2002; Post, 2005). According to the 
symptomatology, bipolar disorder is usually classified as Type 1 (I) or Type 2 (II), 
where bipolar I disorder includes manic and depressive episodes, whereas bipolar II 
disorder is less severe with hypomanic episodes and a more prominent depressive 
feature. Cyclothymia is defined as alternating mood episodes that do not meet criteria 
for severe depression or mania. 
Mania is characterized by e.g. elevated or irritable mood, euphoria, grandiose or 
delusional ideas, impulsivity, reduced need for sleep, increased talkativeness and 
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activity, racing thoughts, distractibility and increased sexuality. In the hyperactive 
episodes, psychotic symptoms may (mania) or may not (hypomania) occur. Bipolar I 
disorder displays many similarities with schizophrenia, and mania can be 
indistinguishable from acute schizophrenia (Mamelak, 1978). Hypomania is a state of 
hyperactivity less severe than mania and not as disabling. Depressive symptoms 
include e.g. persistent feelings of hopelessness, sadness, anxiety, guilt, disturbance in 
sleep and appetite, social withdrawal, reduced sexuality, chronic pain and morbid 
suicidal ideation (see also section 1.4.1). In addition, cognitive impairment, such as 
impaired executive functioning, verbal learning and memory and attention, is common 
in bipolar disorder and can be present in all states of the disease with impact on 
functional outcome (Atre-Vaidya et al., 1998; Martínez-Arán et al., 2004).  
1.3.2 Etiology and risk factors  
The pathophysiology of bipolar disorder is still not known, but family, twin and 
adoption studies reveal a high heritability (Kieseppa et al., 2004; Lichtenstein et al., 
2009). However, no single gene seems to be responsible, rather a complex interaction 
of several genes seems likely. Several susceptibility genes have been identified to be 
associated with bipolar disorder, genes that may also be involved in schizophrenia, 
indicating an overlap in genetic vulnerability (see e.g. Blackwood et al., 2007; 
Lichtenstein et al., 2009; Murray et al., 2004).  
Non-genetic risk factors include various illicit drugs and early life stressors such as 
parental loss, in particular maternal loss (Mortensen et al., 2003). In addition, stressful 
event may induce relapse in bipolar disorder (Ellicott et al., 1990). Notably, sleep 
deprivation may induce mania in some patients and produce an antidepressant effect in 
others (Barbini et al., 1998; Wehr et al., 1987).  
Studies of structural brain abnormalities in bipolar disorder have yielded 
inconsistent results, although some indicate enlargement of the third and lateral 
ventricles (Morgan et al., 2007). 
1.3.3 Hypotheses of bipolar disorder 
The switch phenomenon in bipolar disorder, which most frequently occurs from 
depression to hypomania or mania, is poorly understood, but may be triggered by 
spontaneous (i.e. non-treatment related) or pharmacological interventions with drugs 
through different mechanisms (for review see Salvadore et al., 2010). Suggested 
causative biological factors include abnormalities in catecholamine levels, 
dysregulation of neurotrophic and neuroplastic factors (such as brain-derived 
neurotrophic factor; BDNF), hypothalamic-pituitary-adrenal (HPA) axis hyperactivity 
and circadian rhythms. 
The pathophysiology of bipolar disorder is less well understood than in 
schizophrenia or MDD, although part of the symptomatology overlaps between these 
different disease entities, and no generally accepted animal model for bipolar disorder 
exists. However, a dysregulation of the mesocorticolimbic system that is involved in 
control of emotions, cognition and reward, has been proposed.  
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In support of this notion, D-amphetamine may in healthy individuals induce 
symptoms such as euphoria, reduced need for sleep and increased alertness closely 
resembling those of mania (Angrist et al., 1974; Jacob and Silverstone, 1986). Indeed, 
some results from studies using brain imaging techniques are consistent with the notion 
of enhanced postsynaptic dopamine responsivity in the STR of patients with bipolar 
disorder (Anand, 2000). Bipolar depression may on the other hand be related to a 
hypodopaminergic state, since depressive symptoms may emerge following withdrawal 
of amphetamine after chronic use (Watson et al., 1972). In addition, dopamine agonists 
may effectively reverse depressive symptoms (Goldberg et al., 2004; Silverstone, 1984; 
Zarate et al., 2004). However, administration of L-DOPA and dopamine agonists to 
patients with bipolar depression may also induce a switch into hypomania (Murphy et 
al., 1971; Silverstone, 1984). Further support for this notion includes the fact that acute 
mania is readily treated with APDs with D2 receptor blocking properties.  
The cognitive impairments associated with bipolar disorder may be present in all 
phases of the disease, including the euthymic state, and are proposed to be associated 
with a dysregulation of dopamine and, via D1 receptor-mediated mechanisms, 
glutamatergic transmission in the PFC (see section 1.2.3 and 1.2.4). The notion that 
glutamatergic dysfunction may play an important role in the pathophysiology of 
bipolar disorder has recently been supported by the observation that the NMDA 
receptor antagonist ketamine can produce a robust and rapid antidepressant effect in 
treatment-resistant bipolar depression as well as reduce suicidal ideation (Diazgranados 
et al., 2010a, b; see section 1.4.3). In addition, the NMDA receptor antagonist 
memantine, which may be used to treat psychosis and cognitive dysfunction associated 
with Alzheimer’s disease (Hellweg et al., 2012; Wilcook et al., 2008), has also 
demonstrated an anti-manic and mood stabilizing effect in treatment-resistant bipolar 
disorder (Koukopoulos et al., 2012). Furthermore, both postmortem and genetic 
studies have proposed altered expression of NMDA as well as α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors (Beneyto et al., 2007; Beneyto 
and Meador-Woodruff, 2008; Martucci et al., 2006; Mundo et al., 2003). Among 
other known pharmacological triggers are exogenous corticosteroids and certain 
antidepressant drugs (see Salvadore et al., 2010). 
1.3.4 APDs in the pharmacotherapy of bipolar disorder 
The treatment of bipolar disorder aims to balance the mood without inducing a 
switch to the opposite state. The most commonly used drugs for treatment of bipolar 
disorder are mood stabilizers such as lithium and anticonvulsive drugs, e.g. valproate, 
lamotrigine and carbamazepine. In similarity with the treatment of psychosis in 
schizophrenia, acute mania also responds well to APDs. Several atypical APDs, i.e. 
quetiapine, olanzapine, risperidone, aripiprazole, ziprasidone and most recently 
asenapine, have been approved for acute treatment, as monotherapy or adjunctive 
therapy, of manic or mixed episodes associated with bipolar I disorder in adults. APDs 
are now prescribed to almost 50% of the patients treated for bipolar disorder 
(Gutierrez-Rojas et al., 2010). Furthermore, SSRIs are often used for acute bipolar 
depression although their continued use confers a risk of conversion to mania or rapid 
cycling. In addition, many patients with bipolar disorder are treatment-resistant and 
there is frequently a delay in onset of the effect among existing medications (Judd et al., 
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2002), particularly during depressive episodes (Nierenberg et al., 2006). A combination 
of low to moderate doses of atypical APDs, such as olanzapine, and the SSRI 
fluoxetine have been shown to generate a potent antidepressant effect with a fast onset 
of action in treatment-resistant depression (Dubé et al., 2007; Shelton et al., 2005). 
Notably, monotherapy with quetiapine has been approved for the treatment of bipolar 
disorder, including bipolar depression, and shows in contrast to SSRIs a rapid onset of 
action (Cruz et al., 2010; Keating and Robinson, 2007), although the underlying 
mechanism in not, as yet, fully understood.  
 
1.4 Major depressive disorder 
Major depressive disorder (MDD), also known as unipolar depression, is a common, 
severe chronic and often recurrent affective disorder. It afflicts about 16% of the 
population (Kessler et al., 2003), with twice as high life time prevalence for women 
than men and higher incidence in late spring or early summer. The time course of the 
disorder varies from one episode lasting for weeks to a lifelong recurrence of major 
depressive episodes. The life expectancy for patients with MDD is shorter than normal 
due to an increased mortality from both somatic illnesses (1.5 times normal) and a high 
risk of suicide (21 and 27 times for men and women, respectively; Ösby et al., 2001). 
Over 50% of those committing suicide have affective disorders such as MDD 
(Cavanagh et al., 2003). Thus, major depression is a severe and disabling disorder 
associated with very high socioeconomic cost. 
1.4.1 Symptomatology 
The clinical characteristics of a major depressive episode are similar to those of 
bipolar depression (see section 1.3.1) and the main symptoms are, according to the 
DSM-IV, persistent low mood (more than two weeks) and inability to experience 
pleasure and reward (anhedonia; APA, 2000). Impaired cognition, such as poor 
concentration, impaired working memory and difficulty making decisions, is often 
present and its improvement is considered to determine treatment outcome (McCall and 
Dunn, 2003). In addition, a bias towards negative emotions is typical. In severe cases of 
MDD psychosis may occur.  
1.4.2 Etiology and risk factors  
Despite intensive research, the neurobiological basis and pathophysiology of MDD 
remain largely unknown. Generally, interplay between genes and environmental factors 
are thought to cause MDD (Chopra et al., 2011; Lohoff, 2010). Heritability may play 
an important role in the etiology of MDD, as indicated by family, twin, adoption and 
linkage studies (see Lohoff, 2010). Specifically, polymorphisms in genes regulating the 
serotonin transporter and BDNF have been shown to correlate with depression (aan het 
Rot et al., 2009; Lohoff, 2010; McGuffin et al., 2011). Environmental factors such as 
childhood abuse, ongoing or recent stressful events, reduced ability to cope with stress 
and psychosocial interactions are also likely to be involved (see e.g. Chopra et al., 
2011; Fisher et al., 2012; Popoli et al., 2011; Rosenquist et al., 2011). Furthermore, 
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inflammation has been proposed to be linked to depression (for recent review, see e.g. 
Krishnadas and Cavanagh, 2012).  
1.4.3 Hypotheses of major depressive disorder 
Many factors may be involved in the development of MDD, e.g. dysregulation of 
monoamine transmission, the HPA-axis, neurotrophic factors and cytokines (Chopra et 
al., 2011). Thus, the monoamine deficiency hypothesis of depression emphasizes the 
role of monoamines in the pathophysiology and treatment of depression (for review see 
Carlsson, 1976; Chopra et al., 2011). Despite intense research, direct clinical data 
supporting a causative role of monoamine-deficiency in depression are sparse and 
inconclusive as regards the abnormalities in e.g. plasma, serum, CSF and brain tissue 
and more recently genetic and imaging data. Hence, the monoamine deficiency 
hypothesis still resides largely on indirect pharmacological evidence. Early studies 
showed that the depressogenic effect of reserpine in humans very likely was related to 
depletion of brain monoamines, and, moreover, that the antidepressive effect of 
monoaminoxidase inhibitors was associated with enhanced monoaminergic 
transmission (see Schildkraut, 1965). Furthermore, depressive-like symptoms, such as 
dysphoria, anhedonia, anxiety and insomnia, may emerge following withdrawal from 
sustained use of high doses of cocaine or amphetamine (Gawin and Kleber, 1986; 
Watson et al., 1972). Modern pharmacological treatment of depression includes a 
number of drugs that all enhance monoaminergic transmission in several ways, such as 
mirtazapine exerting α2-adrenoceptor antagonist action, SSRIs, the selective serotonin 
and noradrenaline re-uptake inhibitor (SNRI) venlafaxin, the noradrenaline re-uptake 
inhibitor (NRI) reboxetine and the dopamine and NRI (DNRI) bupropion. As 
mentioned previously, catecholamine projections to the PFC are involved in the control 
of attention, executive functioning and working memory (Goldman-Rakic et al., 2004; 
Robbins and Arnsten, 2009). In addition, dopamine is involved in reward, motivation 
and psychomotor activity which may be altered in depression (see e.g., Dunlop and 
Nemeroff, 2007). In severe MDD, even psychosis may occur, that may be related to 
abnormal dopamine reactivity in striatal areas of the brain (see section 1.2.3). 
Tryptophan is the precursor of serotonin and tryptophan depletion in the diet has 
been found to induce relapse in patients who had previously suffered from recurrent 
episodes of major depression (Smith et al., 1997), indicating a prominent role of 
serotonin in the pathophysiology of depression. With few exceptions, antidepressant 
treatments, including SSRIs, TCAs, 5-HT1A agonists as well as electroconvulsive 
therapy (ECT), may as a common denominator exert their effect through modulating 
the serotonergic system (see Blier et al., 1987; Carlsson et al., 1969; Coppen et al., 
1967). However, the therapeutic response to SSRIs, the most commonly prescribed 
drugs, is often insufficient and usually requires several weeks of treatment before a 
sufficient antidepressant effect is obtained (Trivedi et al., 2006). The mechanism 
behind the delayed onset of antidepressant effect may involve neuroadaptation such as 
desensitization of autoreceptors (Svensson and Usdin, 1978), which corresponds in 
time with the onset of action of traditional antidepressants in MDD (Blier et al., 1990; 
Blier and de Montigny, 1987). The antidepressant effect of serotonin has also been 
proposed to involve activation of 5-HT2A receptors on pyramidal cells of layer V in 
mPFC, thereby enhancing cortical glutamatergic transmission (Aghajanian and Marek, 
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1997; Li et al., 2010; Miner et al., 2003a; Weisstaub et al., 2006). In fact, an altered 
expression of the glutamatergic NMDA receptors subunits NR1 and NR2A has been 
found in MDD (Beneyto and Meador-Woodruff, 2008), indicating a link to cognitive 
dysfunction. Moreover, NR2B selective NMDA antagonists have been found to 
produce an antidepressant action in both preclinical depression models and clinical 
trials (Li et al., 2010; Maeng et al., 2008; Preskorn et al., 2008). Extrasynaptic NR2B 
receptors have been shown to inhibit the mammalian target of rapamycin (mTOR) 
signaling and blockage by selective antagonists or the NMDA receptor antagonist 
ketamine has been demonstrated to re-activate this signaling as well as increase levels 
of synapse-associated proteins and synaptic spine density in the PFC (Li et al., 2010). 
Interestingly, substantial clinical data show that the NMDA receptor antagonist 
ketamine can improve depressive symptoms after a single injection in treatment-
resistant depression with a rapid onset, i.e. within a day compared to weeks for SSRIs, 
and with a sustained effect, as well as reduce suicidal ideation (Berman et al., 2000; 
Ibrahim et al., 2012; Price et al., 2009; Zarate et al., 2006; for review see Maeng and 
Zarate, 2007). Moreover, the ketamine-induced antidepressant effect as well as the 
activation of the mTOR pathway was blocked by a selective AMPA receptor antagonist 
(Maeng et al., 2008; Li et al., 2010), indicating a critical involvement of AMPA 
receptors in the mechanism of action of ketamine. However, due to psychotomimetic 
and dissociative effects, as well as a potential risk of drug abuse, ketamine has limited 
clinical utility (Carpenter, 1999, Perry et al., 2007). A disturbed synaptic plasticity 
seems involved in the pathophysiology of MDD (see e.g. Carlson et al., 2006; Mattson, 
2008) and a considerable amount of studies has shown that ketamine and activation of 
glutamatergic mechanisms as well as stimulation of the mTOR pathway may induce 
synaptic plasticity (see e.g. Hoeffer and Klann, 2010; Li et al., 2010). Stress and 
potentially stress-related diseases such as depression may cause atrophy of pyramidal 
cells in the mPFC, deficits that can be rapidly reversed by ketamine via mTOR-
dependent signaling (Li et al., 2010; Liu and Aghajanian, 2008). The reduced 
hippocampal volume that has been found in MDD (Konarski et al., 2008; Sheline et al., 
2003) may potentially involve such mechanisms.  
1.4.4 APDs in the pharmacotherapy of major depressive disorder 
The current pharmacotherapy of MDD is based on the principle of enhancing 
monoaminergic, particular serotonin and noradrenaline, transmission. The most 
commonly prescribed drugs for the treatment of depression are SSRIs. However, their 
efficacy is clearly not optimal (Lam and Kennedy, 2004; Trivedi et al., 2006). In 
addition, the delayed therapeutic response to SSRIs represents a problem as such. In 
treatment-resistant depression, co-administration of modest doses of atypical APDs to 
SSRIs or SNRIs has been shown to augment the antidepressant effect with a rapid onset 
of action, i.e. appearing within days compared to weeks with antidepressant drugs alone 
(Debattista and Hawkins, 2009; Mahmoud et al., 2007; Nelson and Papakostas, 2009; 
Nemeroff, 2005; Olver et al., 2008; Tohen et al., 2010), although the mechanisms 
involved are not fully understood.  
 
Introduction 
 
  15 
1.5 The dopamine systems  
In the 1950s, Carlsson and colleagues discovered that dopamine, i.e. the precursor to 
noradrenaline and adrenaline, is a transmitter in its own right (Carlsson et al., 1957, 
1958; Carlsson, 1959). However, dopamine may also be co-released from 
noradrenergic neurons (Devoto et al., 2001). The action of dopamine has been 
described in the terms of gating of inputs and modulation of information, in contrast to 
having either an inhibitory or excitatory role. Dopamine is now known to be involved 
in a wide range of behavioral activities such as motor functioning, working memory, 
reward, mood and stress reactions. The dopaminergic neurotransmission is accordingly 
a target for drugs used in the treatment of several neurological and psychiatric 
disorders, including schizophrenia (Carlsson and Lindqvist, 1963; Laruelle et al., 
1996), Parkinson’s disease (Carlsson, 1959; Hornykiewicz, 1962), drug abuse and 
affective disorders (see Dunlop and Nemeroff, 2007; Schildkraut, 1965). 
1.5.1 The dopamine pathways  
The introduction of the formaldehyde histofluorescence method (Falck et al., 1962) 
enabled visualization of the neuronal distribution of monoamine-containing cell. This 
led to the mapping of the dopaminergic neurons in the brain, demonstrating two main 
nuclei, i.e. the substantia nigra (SN; A9) and the ventral tegmental area (VTA, A10; 
Dahlström and Fuxe, 1964; Ungerstedt, 1971). The dopamine system in the central 
nervous system (CNS) is usually divided into four main pathways; the nigrostriatal, the 
mesolimbic, the mesocortical and the tuberoinfundibular pathway (see Figure 1). A 
large group of the dopamine neurons are situated in the SN and project mainly to the 
dorsal STR, i.e. the caudate and the putamen, and constitute the nigrostriatal pathway 
(Andén et al., 1964), which is involved in sensorimotor control and initiation of 
movements. Decreased dopamine transmission due to cell death of dopamine neurons 
in the SN is the main cause of Parkinson’s disease (Hornykiewicz et al., 1962). 
Blockade of the nigrostriatal dopamine pathway is also associated with EPS, i.e. motor 
side effects such as parkinsonism, which frequently occur during treatment with typical 
APDs, but less so with atypical APDs. The dopamine neurons originating in the VTA 
forms the so-called mesocorticolimbic pathway and are further subdivided into two 
pathways according to their efferent projections; the mesolimbic and the mesocortical 
pathway (Moore and Bloom, 1978; Ungerstedt, 1971). The mesolimbic pathway 
innervates subcortical areas, e.g. NAc in the ventral STR, amygdala and hippocampus, 
whereas the mesocortical pathway innervates e.g. the PFC (see section 1.9 and 1.10). 
Finally, the tuberoinfundibular pathway contains neurons with short axons projecting 
from the arcuate nucleus of the hypothalamus to the median eminence and pituitary 
gland via the infundibulum. Dopamine is the predominant inhibitory factor in the 
synthesis and secretion of prolactin (Fitzgerald and Dinan, 2008). Treatment with D2 
blocking drugs such as APDs may therefore cause increased prolactin secretion and 
associated side effects (see section 1.1). 
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Figure 1. Schematic drawing of the 
dopamine pathways in the human 
brain.  
Abbreviations: Am = amygdaloid 
nucleus; Hip = hippocampus;  
Hyp = hypothalamus; NAc = 
nucleus accumbens; P = pituitary 
gland; PFC = prefrontal cortex; Sep 
= septum; SN = substantia nigra;  
STR = striatum; Th = thalamus; 
VTA = ventral tegmental area. 
Modified from (Rang et al., 1999). 
 
 
 
 
 
 
 
1.5.2 Biosynthesis and elimination of dopamine 
Dopamine, as all catecholamines, is formed from the non-essential amino acid 
tyrosine (see Hardman et al., 2001). L-tyrosine is taken up from the blood stream with 
active transporters over the blood-brain barrier (BBB) and into the catecholamine 
neurons, including dopaminergic, noradrenergic and adrenergic neurons in the brain. 
The first enzymatic transformation in the dopamine synthesis is when L-tyrosin is 
hydroxylated into L-DOPA in a rate-limiting step by tyrosin hydrolylase (see Figure 2). 
L-DOPA is furthermore decarboxylated into dopamine by DOPA decarboxylase. 
Dopamine is stored in vesicles in the nerve terminal. This storage can be blocked by 
drugs such as reserpine, which can deplete neuronal terminals of dopamine, 
noradrenaline and serotonin by inhibiting the vesicular monoamine transporter 
(VMAT). Dopamine is released from the catecholamine terminal by a Ca2+-dependent 
exocytic mechanism initiated by a nerve impulse and can also be released dendritically 
(Nissbrandt et al., 1985). Dopamine can also be co-released from noradrenergic 
neurons (Devoto et al., 2001, 2003). The primary mechanism for inactivation of 
dopamine is reuptake into the neurons. Dopamine can be eliminated from the synaptic 
cleft either into the dopamine neuron by a dopamine selective transporter or into 
noradrenergic neurons by a norepinephrine transporter (NET; Carboni et al., 1990). 
These transport proteins can be blocked by inhibitors such as cocaine and various 
antidepressant drugs. Dopamine may be either recycled or metabolized by the 
intracellular enzyme monoamine oxidase (MAO) to dihydroxyphenyl acetic acid 
(DOPAC). Alternatively, extracellular dopamine can be metabolized into 3-
methyltyramine (3-MT) and subsequently to homovanillic acid (HVA) by COMT and 
MAO metabolism. MAO is bound within the surface membrane of the mitochondria 
and exists in two different forms in the brain, namely MAO-A and MAO-B. While 
dopamine, noradrenaline and serotonin all are substrates for MAO-A, MAO-B has a 
preference for dopamine. These enzymes are targets for pharmacotherapies indicated 
for e.g. depression (MAO-A) and Parkinson’s disease (MAO-B). The major metabolite 
in rat brain is DOPAC, while HVA appears to be predominant in the human brain. 
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1.5.3 Dopamine receptors 
The dopamine receptors are G-protein coupled, generating a slow signaling 
through an intracellular cascade involving second messengers (see Beaulieu and 
Gainetdinov, 2011; Hardman et al., 2001). The receptors are categorized in two main 
classes, D1-like and D2-like receptors, and are classified according to their sequence 
homology and effect on signaling systems. The D1-like receptor subtype includes the 
D1 and the D5 receptors, which activate Gαs/olf proteins, stimulating adenylate cyclase 
to increase cAMP. The D2-like receptors include the long and short isoforms of D2 
(D2L and D2S) found to be expressed predominantly post- and presynaptic, 
respectively, as well as the D3 and D4 receptors. The D2-like receptors are coupled to 
Gαi/o proteins and inhibit adenylate cyclase. The dopamine receptors are diffusely 
distributed throughout the brain and the expression differs in regional localization in 
the brain. D1 receptors are the most expressed dopamine receptor in the brain and 
found in most areas innervated by dopamine neurons, e.g. in the STR, the NAc, and 
the frontal cortex (FC). D5 receptors are poorly expressed in the brain compared to 
the D1 receptors. D2 receptors are expressed in almost the same areas as for D1 
receptors, i.e. in the STR, NAc, and to a significant extent in SN and VTA, however 
only to a low extent in the FC. In addition, D2 receptors are found in the pituitary 
gland, regulating the release of prolactin. The distribution of D3 receptors are more 
restricted and found in highest concentrations in the limbic areas such as the shell of 
NAc. The D4 receptors have low expression in the brain and found in e.g. the FC and 
amygdala. While the D1 receptors are expressed postsynaptically, the D2-like 
receptors are found both pre- and postsynaptically. D2 receptors act as autoreceptors 
when located presynaptically and in somatodendritic regions, and adjust the firing 
rate, synthesis and release of dopamine by negative feedback.  
1.5.4 Regulation of dopaminergic transmission in the brain 
The dopamine neurons are regulated by both afferent input and negative feedback 
from autoreceptors. It has been shown that dopamine release in the STR partly is 
regulated by postsynaptic D2 receptors via long loop feedback mechanisms, involving 
Figure 2. A schematic drawing of a 
dopaminergic nerve terminal. 
DA=dopamine; D1=D1-like receptor; 
D2=D2-like receptor. Other abbreviations 
see text. Modified from (Cooper et al., 
2003). 
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e.g. GABAergic neurons, and dependent on dopaminergic nervous impulse flow, 
which has been demonstrated in studies using e.g. APDs or D-amphetamine (Andén et 
al., 1971; Bunney and Aghajanian, 1976a, b, 1978). The activity of dopamine neurons 
in the VTA and SN is also regulated by feedback mechanisms through D2 
autoreceptors located on the dopaminergic soma and dendrites through an inhibitory 
potassium-dependent response, resulting in a hyperpolarization of the neuron and 
reduced firing of the cell (Bunney et al., 1973; Innis and Aghajanian, 1987; Lacey et 
al., 1987). At the nerve terminal, D2 autoreceptors regulate the synthesis and release 
of dopamine (Farnebo and Hamberger, 1971; Imperato and DiChiara, 1988; Kehr et 
al., 1972; see Beaulieu and Gainetdinov, 2011). However, dopamine neurons 
innervating the PFC appear to be sparsely regulated by D2 autoreceptors both as 
regards synthesis-modulating receptors on the nerve terminals and impulse-regulating 
somatodendritic receptors (Chiodo et al., 1984). There is also an interaction between 
the dopamine projections, illustrated by the fact that a reduced mesocortical 
dopamine output may secondarily cause an increased dopamine output in the NAc 
(see e.g. Deutch et al., 1990). Thus, the mesocortical and the mesolimbic dopamine 
projections are differentially regulated. 
Furthermore, experimental studies have shown that noradrenaline neurons may 
regulate dopamine activity by several mechanisms. Thus, noradrenaline was initially 
found to increase dopamine turnover (Andén and Grabowska, 1976; Hervé et al., 
1982). Subsequently, local stimulation of the noradrenergic soma in locus coeruleus 
(LC) was shown to increase burst firing in dopaminergic neurons of the VTA, an 
effect found to be mediated via excitatory α1-adrenoceptors on their cell bodies 
(Grenhoff et al., 1993; Grenhoff and Svensson, 1993). Moreover, extracellular 
dopamine in the cerebral cortex can be co-released with noradrenaline from 
noradrenergic terminals, a process that is primarily controlled by local, presynaptic 
α2-adrenoceptors (Devoto et al., 2001, 2003, 2004; Hertel et al., 1999b; Masana et al., 
2011). Furthermore, as the dopamine-selective transporters in the PFC are sparse, 
dopamine is mainly cleared via the same transporter as noradrenaline (Miner et al., 
2003b; Schroeter et al., 2000; Sesack et al., 1998) and competes for re-uptake from 
the extracellular space in the PFC (Gu et al., 1994). This competition may thus 
generate elevated prefrontal dopamine concentrations in association with increased 
noradrenaline output (Gresch et al., 1995; Moron et al., 2002; Pozzi et al., 1994).  
Glutamatergic pyramidal neurons originating in the PFC (Sesack and Pickel, 1992) 
provide an excitatory input to dopaminergic neurons in the VTA (Gariano and 
Groves, 1988; Sesack and Carr, 2002; Svensson and Tung, 1989). Furthermore, 
activation of glutamatergic NMDA receptors on the dopamine neurons in the VTA 
specifically stimulates burst firing activity (Chergui et al., 1993). The serotonergic 5-
HT1A and 5-HT2A receptors have been found to be highly expressed and co-localized 
on pyramidal cells of the mPFC (Amargós-Bosch et al., 2004; Jakab and Goldman-
Rakic, 1998; Wedzony et al., 2008; Willins et al., 1997) and may indirectly influence 
dopamine transmission. Additional support for a prefrontal glutamatergic regulation 
of the dopamine neurons in the VTA includes studies demonstrating that activation of 
5-HT2A receptors in the mPFC stimulates these dopamine neurons, an effect that can 
be blocked by NMDA receptor antagonists (Bortolozzi et al., 2005). In contrast, 
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although the mechanism is not fully understood, antagonism at the 5-HT2A receptor 
together with D2 receptor blockade enhances cortical dopamine release via a 5-HT1A 
receptor-mediated mechanism (Ichikawa et al., 2001b). The serotonergic neurons 
originating in the midbrain raphe nuclei innervate both the SN and the VTA, as well 
as dopaminergic terminal areas such as NAc, STR and mPFC (Azmitia and Segal, 
1978; Dray et al., 1976; Hervé et al., 1987; Van Bockstaele et al., 1994). Thus, 
stimulation of serotonergic afferent input has been found to inhibit the dopamine cell 
activity in VTA (Kelland et al., 1993).  
Finally, input from inhibitory γ-amino butyric acid (GABA) neurons to the 
dopamine neurons in the VTA is provided both via pathways from other brain areas 
and interneurons within the VTA (see Kalivas, 1993).  
 
1.6 The glutamatergic system  
Glutamate is the most abundant excitatory neurotransmitter in the brain and most 
pathways originate in the cerebral cortex and projects to virtually all regions of the 
brain (see Hardman et al., 2001). Pyramidal cells in the mPFC and hippocampus are 
glutamatergic and are involved in synaptic plasticity, cognition, memory and learning 
(Bortolotto et al., 1999; Castner and Williams, 2007; Collingridge and Bliss, 1995; Li 
et al., 2010). However, excess of glutamate is known to cause neurotoxicity (Olney, 
1994). 
1.6.1 Biosynthesis and elimination of glutamate 
Glutamate is produced from α-ketoglutarate, an intermediate derived from glucose 
in the Krebs cycle (and thus not from glutamic acid, which is a degradation product of 
amino acids found in high concentrations in the CNS). Glutamate is stored in vesicles 
in the nerve terminal and released into the synaptic cleft via interaction with soluble N-
ethylmaleimide-sensitive factor attachment receptor (SNARE) proteins in a calcium-
dependent mechanism when the nerve terminal is depolarized. The primary inactivation 
mechanism for glutamate is reuptake, either into the glutamatergic cells or into the 
adjacent astrocytes, which serves to prevent neurotoxic effects caused by to high 
glutamate levels. In the astrocyte, glutamate is converted to glutamine by the enzyme 
glutamine syntetas. Subsequently, glutamine is released and transported back to the 
glutamate nerve terminal, where it is enzymatically phosphorylated by glutaminase into 
glutamate and re-packed.  
Olivia Frånberg 
 
20 
1.6.2 Glutamatergic receptors 
Glutamate activates a number of ionotropic (ligand-gated) and metabotrophic (G-
protein coupled) receptors. The ionotropic receptors and their respective subunits are 
classified as NMDA receptors (NR1, NR2A-D, NR3A and B subunits), AMPA 
receptors (GluR1, GluR2, GluR3, GluR4 subunits) and kainate receptors (GluR5, 
GluR6, GluR7, KA1, and KA2 subunits), according to their specific pharmacological 
characteristics (see Figure 3; Cull-Candy et al., 2001; Huettner, 2003; Zarate and 
Manji, 2008). The receptors are generally widely distributed in the brain. 
 
Figure 3. Schematic drawing of the ionic excitatory receptors. Glu=glutamate; Gly=glycine; PCP= 
phencyclidine. Modified from (Kandel et al., 1991). 
 
Activation of NMDA receptors is restricted and requires binding of both glutamate 
and the co-agonist glycine. In addition, the ion channel is blocked by extracellular 
magnesium ions at resting potential, which may be removed by e.g. AMPA receptor-
mediated depolarization of the membrane, thereby permitting passage of Ca2+ through 
the pore and into the cell. Glutamate binds with high affinity to NR2 subunits of the 
NMDA receptor (Anson et al., 1998), while glycine binds to the NR1 subunit 
(Kuryatov et al., 1994). The subunits of the NMDA receptor are assembled as a 
heteromer, composed of several NR1 subunits together with at least one NR2 subunit. 
The NR3 subunit may be co-assembled in an NR1/2 complex (Perez-Otano et al., 
2001). NR2B subunits are expressed extrasynaptically and may inhibit the mTOR 
signaling, involved in synaptic plasticity. The properties of the NMDA receptor depend 
on its constitution of the subunits. Psychotomimetic drugs such as PCP and ketamine 
bind to the PCP-site inside the ion channel of the NMDA receptor, indicating a major 
behavioral significance with bearing on mental disorders such as schizophrenia and 
MDD (see Figure 3; see above). 
Both AMPA and kainate receptors are permeable to Na+ and K+ and mediate a fast 
excitatory response (Huettner, 2003; Zarate and Manji, 2008). AMPA receptors are 
often co-expressed with NMDA receptors and its activation results in depolarization of 
the neuronal membrane. Together they are responsible for the expression and control 
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(i.e. via Ca2+ inflow), respectively, of synaptic plasticity. Positive modulators of AMPA 
receptors may facilitate memory and learning and enhance antipsychotic-like effects of 
APDs as well as generate an antidepressant effect with fast onset of action in 
experimental animals (Jardemark et al., 2012; Knapp et al., 2002; Lynch, 1998). 
Moreover, NR2B selective antagonists and the NMDA receptor antagonist ketamine 
have been found to generate an antidepressant effect, that is, dependent on AMPA 
receptor activation in treatment-resistant cases of affective disorder. Thus, a very 
important role of the glutamatergic system in the neurobiology of depression is 
indicated (see section 1.3.3 and 1.4.3). 
The metabotropic receptors (mGluR) are classified as Group I [mGluR1 (a-d) and 
mGluR5 (a, b)], Group II (mGluR2/3), and Group III (mGluR4, mGluR6, mGluR7 and 
mGluR8) according to the specific signaling transduction pathways they activate. 
Interestingly, as mentioned above, mGluR2/3 receptor agonists seem to possess an 
antipsychotic effect as judged from initial clinical trials (Mezler et al., 2010; Patil et 
al., 2007). 
 
1.7 The serotonergic system  
Serotonergic neurons project to virtually all parts of the brain (Azmitia and Segal, 
1978) and have been implicated in the control of appetite, anxiety, aggression, sexual 
behavior, mood, pain and perceptual changes such as visual hallucinations (Roth, 
1994; Barnes and Sharp, 1999). Serotonin is also considered to be involved in the 
pathophysiology of several neuropsychiatric diseases such as anxiety disorders, 
depression and schizophrenia. 
1.7.1 Serotonin pathways  
The central serotonergic neurons are found in nine clusters (denoted B1-B9) along 
the midline of the brain stem, often referred to as the raphe nuclei (see Figure 4). The 
neurons located in the dorsal (DRN) and median (MRN) raphe project together with 
noradrenergic neurons via the medial forebrain bundle (MFB) to a large proportion of 
the brain, e.g. the cortex, hippocampus, limbic systems, thalamus and hypothalamus 
(Azmitia and Segal, 1978; Rang et al., 2012). Notably, the FC and STR are innervated 
by the DRN. The caudally located cells project to brain stem structures, the cerebellum 
and the spinal cord. 
 
 
 
 
 
 
 
Figure 4. Serotonergic pathways in the  
human brain. Am= amygdaloid nucleus;  
C= cerebellum; Hip= hippocampus;  
Hyp= hypothalamus; Sep= septum;  
SN=substantia nigra; Str= striatum,  
Th= thalamus. Modified from  
(Rang et al., 1999). 
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1.7.2 Biosynthesis and elimination of serotonin 
The basic principles of the biochemistry of serotonin are much alike that of 
catecholamines (see Hardman et al., 2001). The precursor amino acid L-tryptophan, 
derived from food protein, passes over the BBB into the serotonergic neurons, where L-
tryptophan is metabolized by tryptophan hydroxylase (see Figure 5). This enzymatic 
metabolism is the major rate-limiting step. However, in contrast to the synthesis of 
catecholamines, the serotonin synthesis is restricted by the availability of its precursor, 
i.e. tryptophan, in the CNS (Aghajanian and Asher, 1971), which thus can be reduced 
by a tryptophan-free diet (Gessa et al., 1974). The resultant precursor 5-
hydroxytryptophan (5-HTP) is sub-sequently decarboxylated by aromatic amino acid 
decarboxylase (AADC) into 
serotonin, which is the final 
product in the CNS, except in 
the pineal gland where serotonin 
is further transformed into the 
hormone melatonin. Serotonin is 
stored in vesicles and released 
by a Ca2+-dependent mechanism 
initiated by nerve impulses. The 
major mechanism for 
elimination of serotonin from 
the synaptic cleft is re-uptake 
into the neurons by the serotonin 
transporter. The termination of 
the activity of serotonin can also 
be acquired through sequential 
enzymatic degradation by 
MAO-A and aldehyde 
dehydrogenase into 5-
hydroxyindole acetic acid (5-
HIAA), which is the primary 
serotonin metabolite.  
1.7.3 Serotonergic receptors 
The serotonin receptors consist of 14 subtypes (5-HT1-7) of which all are G-protein 
coupled, with the exception of the 5-HT3 receptor which is a ligand-gated ion channel 
(Barnes and Sharp, 1999). The 5-HT1 receptors (5-HT1A, B, D, E, F) are negatively coupled 
to adenylate cyclase. The 5-HT1A receptors may function as autoreceptors on the soma 
and dendrites of the neuron regulating cell firing but are also located postsynaptically in 
the PFC and the hippocampus. The 5-HT1B and 5-HT1D receptors are rather similar, 
both having an autoreceptor function. They are found in high density in the basal 
ganglia on nerve terminals but also both pre- and postsynaptically on other neurons. 5-
HT1D receptors are furthermore found in the hippocampus. 5-HT1E receptors are found 
in high density in caudate nucleus and putamen and are also detected in the 
hippocampus and amygdala, however their functional significance is not well 
characterized. Biochemically, the 5-HT2 receptors (5-HT2A, B, C) activate phospholipase 
Figure 5. Schematic drawing of a serotonergic neuron. 5-HT= 
serotonin. Other abbreviations see text. Modified from (Cooper 
et al., 2003). 
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C (PLC). PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP2), which in turn 
causes an increase in inositol triphosphate (IP3) and diacylglycerol (DAG). Whereas 
the 5-HT2A and 5-HT2C receptors are found centrally, 5-HT2B receptors are mainly 
located in peripheral neurons. The 5-HT2A receptors are found with highest density in 
the FC, primarily distributed postsynaptically on glutamatergic pyramidal neurons of 
layer V, but also to minor extent on GABAergic interneurons (Jakab and Goldman-
Rakic, 1998; Willins et al., 1997). 5-HT2C receptors are found in high density in SN and 
caudate nucleus, but are also detected in cortical and limbic structures. The 5-HT1A 
receptors are highly co-localized with 5-HT2A receptors in the mPFC, but are, as 
mentioned previously, functionally opposing each other (Amargos-Bosch et al., 2004; 
Wedzony et al., 2008). The 5-HT2A, 5-HT2C and 5-HT1A receptors have been 
extensively studied since several atypical APDs possess high affinity for these 
receptors (see e.g. Meltzer et al., 2003b). 
5-HT3 receptors are excitatory ligand-gated ion channels, extensively expressed in 
the lower brain stem and involved in pain regulation. The 5-HT4, 5-HT6 and 5-HT7 
receptors are excitatory and positively coupled to adenylate cyclase. 5-HT4 receptors 
are expressed e.g. in STR and hippocampus. 5-HT6 receptors are expressed in caudate 
nucleus, NAc and hippocampus. 5-HT7 receptors are expressed in thalamus, 
hypothalamus and hippocampus with generally lower levels in areas such as the 
cerebral cortex and amygdala. The 5-HT5 receptor class (5-HT5A, B) is the least well 
known among the serotonin receptors, although found to be negatively coupled to 
adenylate cyclase. 
 
1.8 The noradrenergic system  
In the 1950s noradrenaline was recognized as a neurotransmitter in the central 
nervous system (Vogt, 1954). Since then, the noradrenergic system has been shown to 
be involved in the control of e.g. attention, arousal reactions and exploratory responses 
to environmental stimuli, especially associated with novelty or fear (Aston-Jones et al., 
1999; Svensson and Mathé, 2002) and noradrenaline has also been linked to e.g. mood 
disorders and schizophrenia (see e.g. Svensson, 2003a; Robbins and Arnsten, 2009; 
Yamamoto and Hornykiewicz, 2004) and the modes of action of various drugs used to 
treat these disorders. 
1.8.1 The noradrenergic pathways  
The location and projection of noradrenergic neurons were originally described in 
the sixties (Andén et al., 1966; Dahlström and Fuxe, 1964; Ungerstedt, 1971). The 
noradrenergic cell bodies are organized into a number of small clusters in the pons and 
medulla and are usually divided into two major subgroups; the LC and the lateral 
tegmental system (see Figure 6). The LC is the most prominent cluster of noradrenergic 
neurons. The neurons project through the MFB and diffusely innervate large areas of 
the brain, e.g. the cerebral cortex, limbic system, hypothalamus and cerebellum. The 
lateral tegmental system shows more diffuse distribution of cells in the medulla and 
pons. While its ascending pathways mainly projects to amygdala and hypothalamus, the 
descending pathway projects to the spinal cord. 
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1.8.2 Biosynthesis and elimination of noradrenaline 
The basic processes for synthesis, storage, release and degradation of noradrenaline 
are similar to those of dopamine. Synthesis of noradrenaline follows the same route as 
that of dopamine, however, noradrenergic cells also contain the enzyme dopamine β-
hydroxylase, converting dopamine to noradrenaline (see Figure 7; see Hardman et al., 
2001). Following its release, noradrenaline is eliminated from the synaptic cleft by a 
reuptake mechanism involving the NET. Circulating noradrenaline is subject to 
sequential metabolic degradation by the enzymes COMT and MAO, forming the major 
CNS metabolite 3-methoxy-4-hydroxyl-phenethylenglycol (MHPG). 
 
 
 
 
 
 
 
 
 
Figure 7. Schematic drawing of a 
noradrenergic neuron. α= α-
adrenoceptor; β= β-adrenoceptor; 
NA= noradrenaline; NM= 
normetanephrine; MHPG= 3-
methoxy-4-hydroxy-phenylglycol. 
Modified from (Cooper et al., 2003). 
 
Figure 6. Noradrenergic pathways in the 
human brain. Am= amygdaloid nucleus; 
C=cerebellum; Hip= hippocampus; 
Hyp= hypothalamus, LC= locus 
coeruleus; LTG= lateral tegmental group; 
MFB= medial forebrain bundle; Sep; 
septum; Str= striatum; Th= thalamus. 
Modified from (Rang et al., 1999). 
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1.8.3 Noradrenergic receptors 
The noradrenaline receptors are G-protein coupled and categorized in three major 
types, namely α1, α2- and β-adrenoceptors. The receptors are further subclassified as 
α1A, B, D, α2A, B, C and β1, 2, 3 (Bylund et al., 1994; Civantos Calzada and Aleixandre de 
Artiñano, 2001). All of the receptors except for the β3 receptor are expressed in the 
CNS, and both α1- and α2-receptors are widely distributed in the brain (Nicholas et al., 
1996). α1 receptors are mostly postsynaptic but may also occur presynaptically and 
their stimulation activates Gq and subsequently the PLC/IP3 pathway (Bylund et al., 
1994).  
α2A- and to some extent also α2C-adrenoceptors are located predominantly 
presynaptically but may also be found postsynaptically, e.g. in the brain stem (Lee et 
al., 1998; Nörenberg et al., 1997). At the nerve terminal in the FC, α2-adrenoceptors 
may function both as autoreceptors and heteroreceptors and hereby regulate the release 
of noradrenaline, dopamine as well as serotonin, and in addition the firing activity of 
pyramidal neurons (Devoto et al., 2004; Gobert et al., 1998; Hertel et al., 1999b; 
Svensson et al., 1975; Wang et al., 2011). Stimulation of α2-adrenoceptors normally 
results in a hyperpolarization of the target neuron and inhibition of adenylate cyclase 
and thus cAMP formation, thereby regulating the release of the transmitter (Limbird, 
1988). β1 and β2 receptors are entirely postsynaptic on noradrenaline (or adrenaline) 
target neurons and glia cells, and their activation results in an increase in cAMP 
formation by adenylate cyclase via stimulatory G-proteins (see Nicholas et al., 1996; 
Tate et al., 1991). 
 
1.9 The prefrontal cortex  
The PFC in the human brain is a region highly involved with the control of 
cognition and emotions, function modalities that are usually severely affected in major 
psychiatric disorders such as schizophrenia, bipolar disorder and MDD (Goldman-
Rakic et al., 2000; Öngur and Price, 2000; Uylings et al., 2003). Hypofrontality has 
been especially associated with schizophrenia (Andreasen et al., 1992; Ingvar and 
Franzén, 1974; Weinberger et al., 1994) and found to be related to certain aspects of 
cognitive dysfunction as well as negative symptoms (da Silva Alves et al., 2008; 
Driesen et al., 2008; Tan et al., 2007). There are anatomical and functional similarities 
of the dorsolateral PFC in humans and primates and the mPFC in the rat (Öngur and 
Price, 2000; Uylings et al., 2003), although the rat PFC is less well developed and the 
relative volume much smaller. Four different main areas are included in the mPFC of 
the rat: the medial agranular, the anterior cingulate, the prelimbic and the infralimbic 
cortex (Berendse and Groenewegen, 1991; Hoover and Vertes, 2007; Uylings et al., 
2003). These areas are heavily connected with each other and to the brain areas 
projecting to the mPFC, including the thalamus and basal ganglia as well as 
monoaminergic nuclei such as the VTA, the DRN and the LC (see Hoover and Vertes, 
2007; Kuroda et al., 1996; Uylings et al., 2003). Atypical APDs such as clozapine 
increases dopamine output in the mPFC and secondarily, via D1 receptors, facilitate 
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glutamatergic NMDA receptor-mediated transmission in pyramidal neurons of the 
mPFC, a mechanism highly implicated in cognitive functioning (Castner and Williams, 
2007; Chen and Yang, 2002; Goldman-Rakic et al., 2000; Marcus et al., 2005; Ninan et 
al., 2003a; Sawaguchi and Goldman-Rakic, 1991). The dopamine regulation in the 
mPFC is rather complex and also dependent on noradrenergic regulation since the DAT 
is sparse and dopamine inactivation thereby is dependent on re-uptake by the NET 
(Pozzi et al., 1994; Sesack et al., 1998).  
 
1.10  The nucleus accumbens 
The subcortical structure NAc is the main part of the ventral STR and is densely 
innervated by dopaminergic neurons from the mesolimbic pathway. NAc is generally 
involved in emotional and motivational processing as well as reward-related 
functioning. Dysfunction of ventral striatal areas have been shown to be correlated with 
e.g. psychosis, mania and addiction. In this thesis, the two main subdivisions of the 
NAc, i.e., the core and shell (Zaborszky et al., 1985), have been further studied. The 
core region has generally been associated with motor control and the shell region rather 
with control of drive and emotion (Deutch et al., 1992; Deutch and Cameron, 1992). 
Atypical APDs, such as clozapine, preferentially increase dopamine output in the shell 
of NAc, whereas typical APDs, e.g. haloperidol, increase the dopamine output 
preferentially in the core region (Marcus et al., 1996, 2000, 2002).  
 
1.11   Asenapine 
Asenapine is the most recently approved APD for treatment, as monotherapy or 
adjunctive therapy, of schizophrenia and acute manic or mixed episodes associated 
with bipolar I disorder in adults in the United States and for treatment of moderate to 
severe manic episodes associated with bipolar I disorder in adults in Europe (EMA, 
2010; FDA, 2009).  
The chemical structure of asenapine is tetracyclic and similar to those of the 
antidepressant drugs mianserin and mirtazapine. Furthermore, asenapine possesses a 
multireceptor binding profile, with high affinity for several serotonergic (5-HT1A, 5-
HT2A, 5-HT2B, 5-HT2C, 5-HT6, 5-HT7), adrenergic (α1, α2) and dopaminergic (D1, D2, 
D3) receptors with a minimal muscarinic affinity (Schotte et al., 1996; Shahid et al., 
2009). Notably, it has higher affinity for e.g. 5-HT2A/2C, 5-HT6, 5-HT7 and α2B-
adrenergic receptors than for D2 receptors (Shahid et al., 2009). Asenapine exerts 
antagonistic activity at these receptors, with the exception of a partial agonistic action 
which has been established for the 5-HT1A receptor (Ghanbari et al., 2009; Shahid et 
al., 2009). The receptor binding profile slightly differs from those of e.g. risperidone (5-
HT1A and 5-HT6), olanzapine (5-HT1A and α2) and clozapine (muskarinic M1-4: Schotte 
et al., 1996; Shahid et al., 2009). Yet, the basic pharmacology of asenapine at the 
system level in brain was at the initiation of this study far from understood. 
In clinical studies, asenapine has demonstrated potent efficacy on positive symptoms 
in schizophrenia (Kane et al., 2010; Potkin et al., 2007; Schoemaker et al., 2010, 2012). 
Its effects on negative symptoms have been shown to be similar to or more efficacious 
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than those of risperidone and olanzapine (Potkin et al., 2007; Schoemaker et al., 2010, 
2012). Several preclinical studies as well as preliminary clinical data indicate an effect 
of asenapine also on cognitive impairment (Elsworth et al., 2012; Jardemark et al., 
2010; Potkin et al., 2006; Snigdha et al., 2011).  
In bipolar disorder, asenapine has been shown to be efficacious in the treatment of 
mixed or manic episodes associated with bipolar I disorder (McIntyre et al., 2009a,b, 
2010a, b). Asenapine has also been observed to improve depressive symptoms in 
bipolar I disorder and schizophrenia as well as in a preclinical model of depression 
(Kane et al., 2010; Marston et al., 2011; Szegedi et al., 2011). Asenapine is generally 
well-tolerated with low propensity to induce EPS or anticholinergic effects and has 
little effect on metabolic parameters and body weight or prolactin secretion (Kane et al., 
2010; McIntyre et al., 2009a,b, 2010a, b; Potkin et al., 2007; Schoemaker et al., 2010, 
2012).  
Against the above background, the present set of preclinical studies were undertaken 
to reveal the various mechanisms of action of asenapine in brain that might underlie 
and explain these clinical observations at the systems level, and allow for a more 
thorough comparison with already well established psychopharmacological drugs with 
similar clinical utility. 
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2 SPECIFIC AIMS OF THIS STUDY 
 
• To investigate the significance of additional α2-adrenoceptor blockade in 
combination with low doses of risperidone for its antipsychotic-like efficacy, 
EPS liability, effects on cortical and sub-cortical dopamine efflux and cortical 
NMDA receptor-mediated transmission in pyramidal neurons in the mPFC.  
 
• To examine the novel APD asenapine as regards its antipsychotic-like effect 
and EPS liability, and effects on dopamine output in terminal regions of both 
the nigrostriatal and mesocorticolimbic systems in the brain as well as cortical 
NMDA receptor-mediated transmission in pyramidal neurons.  
 
• To explore the potentially differential mechanisms of action of asenapine on 
monoaminergic systems in the mPFC and NAc, with particular focus on 
dopamine outflow. 
 
• To specifically evaluate the involvement of α2-adrenoceptor and 5-HT2A 
receptor blockage in the effects of asenapine on monoamine release in the 
mPFC in vivo. 
 
• To explore if adjunctive treatment with asenapine may enhance the effects of 
escitalopram on brain neurotransmitters and receptors of critical importance for 
antidepressant activity. 
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3 MATERIALS AND METHODS 
3.1 Animals 
Male albino rats were used in all studies. Adult Wistar rats (BK Universal, 
Sollentuna, Sweden and Charles River Laboratories, Germany) were used for the 
behavioral, in vivo microdialysis and ex vivo radioligand binding experiments, whereas 
Sprague–Dawley rats (BK Universal and Charles River Laboratories) were used for the 
in vitro electrophysiological, in vivo electrophysiological and in vivo voltammetry 
experiments.  
The animals were housed under standard laboratory conditions in temperature and 
humidity controlled facilities. Food and tap water were available ad libitum. For the 
microdialysis, voltammetry, electrophysiological and radioligand binding experiments 
the animals were kept on a 12:12 h light/dark cycle (lights on at 6:00 A.M.), whereas 
for the behavioral tests, animals were maintained on a reversed 12:12 h light/dark cycle 
(lights off at 6:00 A.M.). All experiments were performed between 8:00 A.M. and 6:00 
P.M. The animals were acclimatized for at least 5 days before experiments. All effort 
was made to minimize the number of animals used.  
In general, all experiments were approved by, and conducted in accordance with, the 
local Animal Ethics Committee, Stockholm North, and the Karolinska Institutet, 
Sweden. Permit numbers: N11/00, N339/02, N340/02, N18/04, N93/05, N317/05, 
N335/05, N338/05, N01/07, N73/08, N387/08, N389/08 and N493/11. However, the 
radioligand binding experiments were performed at Johnson and Johnson 
Pharmaceutical Research and Development, Beerse, Belgium and all procedures were 
approved by the animal care and use committee of Johnson and Johnson 
Pharmaceutical Research and Development and conducted in strict accordance with the 
European Communities Council Directive of 24 November 1986 (86/609/EEC). 
 
 
3.2 Drugs 
The following drugs were used: 
Antipsychotic drugs 
Asenapine and 3H-asenapine were gifts from Schering-Plough, Newhouse, UK.  
Risperidone was a gift from Johnson & Johnson Pharmaceutical Research & 
Development, division of Janssen Pharmaceutica NV, Beerse, Belgium.  
Antidepressant drugs 
Escitalopram was generously obtained from Lundbeck A/S, Denmark. 
Selective noradrenergic drugs  
Idazoxan (an α2A-adrenoceptor antagonist) and clonidine (an α2A-adrenoceptor agonist) 
were purchased from Sigma-Aldrich, St. Louis, USA.  
Selective serotonergic drugs 
M100907 [R-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-flourophenyl)ethyl]-4-piperidine 
methanol; a 5-HT2A receptor antagonist] was obtained from Marion Merrell Dow, 
USA. DOI [1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride; a 5-
HT2A/2C receptor agonist] was obtained from RBI, USA. 
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Glutamatergic drugs 
(RS)-AMPA was purchased from Ascent Scientific, Bristol, UK, and glycine and 
NMDA were purchased from Sigma-Aldrich, St. Louis, USA. 
Other drugs 
Tetrodotoxin (TTX; a voltage-gated Na+ channel blocker), and bicuculline (a GABAA 
receptor antagonist) were obtained from Tocris, Bristol, UK and Ascent Scientific, 
Bristol, UK, respectively. 
 
For the in vivo microdialysis experiments, drugs were generally dissolved in 
physiologic saline (0.9% NaCl) for systemic injection. However, risperidone was 
dissolved in a minimal amount of glacial acetic acid and subsequently diluted in 5.5% 
glucose for systemic administration. For local application, drugs were generally 
dissolved in purified water, although escitalopram was dissolved in dimethyl sulfoxine 
and M100907 in a minimal amount of glacial acetic acid, and then brought to desired 
stock concentration by addition of purified water. For the local application via reverse 
microdialysis, the drugs were subsequently diluted in physiologic perfusion solution to 
reach the final drug concentration. For the in vitro electrophysiological experiments, the 
stock solutions were diluted in Ringer’s solution.  
 
Systemic administration was performed either by subcutaneous (s.c.) injections or 
intraperitoneal (i.p.) injections at a volume of 1.0 ml/kg (behavioral experiments and in 
vivo microdialysis), or by intravenous (i.v.) injections in the jugular vein at a maximum 
volume of 0.2 ml/kg (in vivo voltammetry and in vivo extracellular single cell 
recording). For local administration and recovery experiments (microdialysis), the 
drugs were infused via the probe at a rate of 2.5 µl /min. All drugs used in the in vitro 
electrophysiological experiments, including NMDA and AMPA, were administered via 
bath application. 
 
 
3.3 Conditioned avoidance response  
3.3.1 Procedure 
The conditioned avoidance response (CAR) test is a two-way active avoidance 
response test with a negative reinforcer, proceeded as follows. Rats were trained and 
tested in conventional shuttle boxes (530×250×225 mm; Kungsbacka Mät- och 
Reglerteknik, Fjärås, Sweden), divided into two compartments of equal size by a 
partition with an opening, as described previously (Salmi et al., 1994b). Upon 
presentation of a conditioned stimulus (CS; an 80 dB white noise), the rats had 10 s to 
avoid the unconditioned stimulus (UCS; an intermittent electric footshock of 0.3- 0.4 
mA [intershock interval 2.5 s, shock duration 0.5 s]), by moving from one compartment 
of the shuttle box into the other. White noise is produced by combining equal intensity 
sounds of all different frequencies to form a broad spectrum type of sound. The 
position of the rat, registered via photocells, was automatically transferred to the 
computer where the following behavioral variables were recorded (see Table 1): 
avoidance, escape, escape failure and inter-trial crosses. The animals were trained for 
five days, and each training session consisted of approximately 20 trials randomly 
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distributed over 15 min. Only animals reliably performing at a level of >85% avoidance 
were included in the study. Experiments were preceded by a pre-test and experiment 
sessions, lasting 10 min, were conducted 20, 90 and 240 min after injection of the drug 
or vehicle. Experimental days were separated by at least two non-experimental days. 
The animals were tested in a counterbalanced change-over design serving as their own 
controls (Li, 1964).  
 
 
  Behavioral variables     Definition 
  Avoidance Response to CS within 10 s 
  Escape Response to CS + UCS (a maximum of 60 s) 
  Escape failure Failure to avoid and escape the UCS by  
moving to the opposite compartment within 60 s  
  Inter-trial crosses Movement between compartments that occur in  
the absence of either stimulus 
 
 
3.3.2 Methodological consideration 
The CAR test has been used since the 1950s and has over time shown high 
predictive validity for antipsychotic activity (Arnt, 1982; Courvoisier, 1956; Janssen et 
al., 1965, 1966; Wadenberg, 2010; Wadenberg and Hicks, 1999). In the CAR test, 
animals exposed to drugs with antipsychotic-like activity exhibit a reduced response to 
the CS, i.e. avoidance behavior, however moving to the opposite compartment when 
the UCS is presented, i.e. escape behavior. With a selective suppression of avoidance 
without induced escape failure, the APDs can be distinguished and separated from e.g. 
benzodiazepines and barbiturates, which may also suppress avoidance however at doses 
also affecting escape behavior. Furthermore, the dose needed for APDs to produce 
antipsychotic-like effect, i.e. approximately 80% suppression of CAR (Wadenberg et 
al., 2001b), is estimated to produce a striatal D2 receptor occupancy closely correlating 
to that needed for sufficient therapeutic response in schizophrenia (Farde et al., 1988; 
Farde and Nordström, 1992; Wadenberg et al., 2001b; Zipursky et al., 2005), and might 
thus help to explain the high predictive validity of this test. The mechanisms and 
structures in the brain involved in the antipsychotic-induced suppression of CAR are 
still not fully understood. However, local application of a selective D2 receptor 
antagonist has demonstrated that the dopaminergic transmission in the nucleus 
accumbens is involved, i.e. suggesting that the CAR effect is mediated primarily via 
mesolimbic dopaminergic transmission (Wadenberg et al., 1990). These findings are in 
line with the notion that psychotic (positive) symptoms are due to a hyperreactivity in 
the forementioned region (Abi-Dargham et al., 1998; Laruelle et al., 1996).  
 
Table 1. Behavioral variables recorded in the conditioned avoidance response (CAR) test. 
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3.4 Catalepsy 
3.4.1 Catalepsy procedure 
Catalepsy was observed in a dimly lit room by placing the animals on an inclined 
grid (60°) for a maximum of 2.25 min. The animals were allowed 30 s of adaptation on 
the grid before observations started. 
The catalepsy was scored from 0 to 
5, according to the time (square 
root transformation) the rat 
remained immobile (see Table 2; 
Ahlenius and Hillegaart, 1986). If 
the rat remained immobile for 0.08 
min, it was scored as 0, etc. 
Observations were performed 30, 
60, and 120 min after drug or 
vehicle injection. Each animal 
received only one treatment. 
3.4.2 Methodological consideration 
The catalepsy test is a robust preclinical test for prediction of EPS liability (Arnt et 
al., 1981; Wadenberg, 1996). Catalepsy in laboratory animals can be described as a 
state of motor rigidity which makes the animal incapable to correct an externally 
imposed unnatural body postures and has been found to correlate well to EPS, a 
parkinsonian-like motor side effect observed relatively frequently predominantly in 
patients treated mainly with typical APDs (see section 1.1).  
The mechanism of action of catalepsy has been extensively investigated and is 
suggested to be primarily due to high D2 receptor blockade in the STR with a 
consequential imbalance in the dopaminergic and cholinergic systems (Arnt et al., 
1981; Fog et al., 1968; Sanberg, 1980). Catalepsy usually appears at about 80% striatal 
D2 occupancy (Wadenberg et al., 2000, 2001b), which corresponds well to clinical data 
where the risk for EPS at this level of D2 receptor blockade becomes very high in 
human (Farde et al., 1988; Zipursky et al., 2005). However, some atypical APDs, i.e. 
clozapine and quetiapine, do not induce catalepsy even in very high dosage (Costall et 
al., 1978; Wadenberg et al., 2001b). 
 
3.5 In vivo microdialysis in freely moving animals 
3.5.1 Surgery and microdialysis procedure 
A detailed description of the microdialysis technique can be found in all papers 
included in this thesis. Briefly, rats were anesthesia and mounted into the stereotactic 
frame. Thereafter, a concentric probe was implanted into the brain area of interest 
(mPFC, FC, NAc, STR or VTA), in accordance to coordinates in the atlas of Paxinos 
and Watson (1998). After surgery, the animals were allowed about 48h recovery in the 
animal facilities before experiments. Dialysis experiments were conducted after 
connection of the implanted probe to the sampling equipment and performed in awake 
Catalepsy scores Time (min) 
  0   0 - 0.08 
  1   0.09 - 0.35 
  2   0.36 - 0.80 
  3   0.81 - 1.42 
  4   1.43 - 2.24 
  5   >2.25 
Table 2. Catalepsy is considered to begin at a 
score of 2 (see Wadenberg et al. 2001b). 
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and freely moving rats. During experiment, the probe was constantly perfused with 
physiological perfusion solution, i.e. an artificial cerebrospinal fluid. Using high-
performance liquid chromatography (HPLC) coupled to electrochemical detection in a 
high sensitive analytical cell, separation and quantification, respectively, of the 
neurotransmitters and their metabolites in the dialysate was accomplished. 
Administration of the drug was performed after a stable outflow of the 
neurotransmitters. After completion of dialysis experiment, histological verification of 
probe placement was performed. 
3.5.2 Methodological consideration 
The microdialysis technique is widely used for detection of extracellular 
concentrations of substances in tissues, usually in vivo (Ungerstedt, 1991). The 
technique, by means of a small probe equipped with a semipermeable membrane, 
mimics the function of the blood vessels, allowing substances under a specific diameter 
to passively diffuse across the membrane along a concentration gradient. It also enables 
both administration and collection of substances to, as well as from a target area. In 
addition, samples from awake and freely moving animals can be sampled continuously 
over a long period of time (hours). However, due to the poor recovery of 
neurotransmitters over the membrane, the temporal resolution is limited (15 - 30 
minutes sampling time depending on brain area studied). Furthermore, since the probe 
(300 µm in diameter) is rather large the implantation procedure causes local tissue 
damage and reduces the spatial resolution.  
 
3.6 In vitro recovery over the microdialysis membrane  
In vitro dialysis was performed in a test tube containing a fixed concentration of 
asenapine with 3H-asenapine. A microdialysis probe with an active surface 
corresponding to the length of mPFC probes was lowered into the solution and perfused 
with physiological perfusion solution. Samples were collected every 30 minutes and 
analyzed in a β-counter. The values were compared to a standard curve made by known 
concentrations of 3H-asenapine. 
3.6.1 Methodological consideration 
The employment of local administration of asenapine by reverse dialysis makes the 
concentrations reaching the brain difficult to assess. Therefore, using a dialysis probe 
within an in vitro setting, the inverse recovery of 3H-asenapine passing through the 
dialysis membrane was investigated. However, the amount of drug reaching the tissue 
in vivo also depends on several other parameters such as the molecular weight of the 
compound and to the post-implantation gliosis (Nomikos et al., 1990; Robinson and 
Camp, 1991).  
 
3.7 In vivo voltammetry  
The in vivo voltammetry technique is described in detail in paper II. Briefly, rats 
were pretreated with the non-selective monoamine oxidase inhibitor pargyline and 
anesthetized. A tracheal catheter, as well as a jugular and a femoral vein catheter were 
inserted for i.v. administration of asenapine and continuous infusion of the anesthetic 
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drug, respectively. The rat was mounted in a stereotaxic instrument and carbon fiber 
electrodes (active portion 12 µm thick and 500 µM long) were inserted into either the 
core or the shell region of NAc according to the atlas of Paxinos and Watson (1998). A 
potential was applied to the electrode, allowing electroactive substances, e.g. 
catecholamines, in the close proximity of the electrode surface to oxidize and the 
catechol oxidation current was recorded every minute. After a stable baseline had been 
achieved, the animals received an injection (i.v.) of saline to exclude nondrug-specific 
effects, and 10 min later, the drug was injected. At the end of each experiment, an 
electrolytic lesion was made through the carbon fiber electrode for the following 
histological verification of the recording site.  
3.7.1 Methodological consideration 
The in vivo voltammetry is used to measure neurotransmitter levels in the brain, in 
similarity with microdialysis (see above). The general principle for the voltammetry 
technique is based on the observation that monoamines easily can be oxidized and 
thereby quantified using electrochemical analysis.  
In comparison with the aforementioned microdialysis technique, this method has 
higher temporal resolution, which enables identification of rapid and transient effects. 
The use of a very fine electrode (12 µm in diameter) enables a higher spatial precision, 
which allows comparison of small areas of the brain e.g. the core and shell of the NAc. 
In addition, the injury by the electrode, compared to that of the probe used in the 
microdialysis, is diminished. In our experimental setting, the animal is required to be 
anesthetized during the experiment. Although chloral hydrate is considered to interfere 
minimally with the receptors studied, its influence is not known. However, all animals 
are equally treated and the results are compared with controls treated in the same way 
(see also section 3.8.1). The activation of the electrode surface by an electrochemical 
treatment improves the selectivity and sensitivity of the measurement, i.e. allows the 
separation of the ascorbic acid from the catechols. Further the pre-treatment of the rats 
with pargyline prevents formation of DOPAC, thus minimizing the interference of 
DOPAC with the catechol peak (Gonon, 1988; Gonon et al., 1984). However, the 
limitation of this method is the incapability to distinguish between dopamine and its 
metabolite DOPAC or other catecholamines.  
In conclusion, there are several differences between the voltammetry and 
microdialysis techniques which can be used to complement each other when studying 
pharmacological manipulations of neurotransmitters in the brain. 
 
3.8 Extracellular single-cell recording in vivo 
The procedures for extracellular single-cell recording are described in detail in Paper 
III of this thesis. Rats were anesthetized (chloral hydrate) and mounted in a stereotaxic 
frame. Anesthesia was maintained throughout the experiment. A recording electrode 
was prepared and lowered into a hole drilled in the skull above the VTA or LC, 
according to coordinates in the atlas of Paxinos and Watson (1998). Experiments were 
performed on cells with electrophysiological characteristics corresponding to those 
previously described for dopamine cells in the VTA and noradrenergic cells in the LC 
(Graham and Aghajanian, 1971; Wang, 1981). Extracellular electrical activity was 
amplified, filtered, discriminated and monitored using an oscilloscope and an 
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audiomonitor. Average firing rate was calculated as spikes per second (Hz). The onset 
of a burst was defined as an interspike time interval (ISI) of less than 80 ms and burst 
termination as the next ISI exceeding 160 ms (Grace and Bunney, 1984). Burst firing in 
VTA dopamine neurons was expressed as the percentage of spikes fired in bursts. Only 
one cell was studied in each animal. 
After completion of the experiment, the recording site was verified histologically. 
Only animals with correct electrode placement were included in the study. 
3.8.1 Methodological consideration 
The extracellular single-cell recording technique in vivo is frequently used to study 
pharmacological effects on cell firing in different brain areas. In this technique the 
animal is required to be anesthetized during the experiment. The influence of the 
anesthetic drug, chloral hydrate, remains unknown and has to be taken into account in 
the interpretation of the results. However, the results are correlated with control animals 
treated in the same way (see also section 3.7.1). 
 
3.9 Intracellular single-cell recording in vitro 
The intracellular single-cell recording technique in vitro is described in detail in 
paper I and II. Using voltage clamp, the voltage is hold constant (clamped), allowing 
measurement electric currents over the cell membrane, mediated by a specific 
activation of a receptor/ion-channel complex (e.g. AMPA and NMDA receptors). 
3.9.1 Preparation of slice 
Briefly, the rats were decapitated under anesthesia. The brains were then rapidly 
removed and cooled in ice-cold Ringer’s solution aerated by 95% O2 / 5% CO2. The 
brains were then cut coronally to produce 450 µm slices. The brain slices were kept 
submerged in aerated Ringer’s solution at room temperature for at least 1 h to allow for 
recovery. A single slice containing mPFC was then transferred to a recording chamber, 
for electrophysiological recording. The chamber was continuously perfused by aerated 
Ringer’s solution.  
3.9.2 Intracellular recording 
Intracellular recordings of both AMPA- and NMDA-induced currents in pyramidal 
cells in layer V and VI of the rat mPFC in slice preparations (approximately 
anterioposterior +3.2 mm from bregma) were performed in the voltage-clamp mode 
(see Arvanov et al., 1997; Arvanov and Wang, 1998; Marcus et al., 2012). Electrodes 
were pulled from borosilicate glass capillaries and filled with 2 M KAc and used for 
recording the mPFC neurons with an amplifier. Single electrode voltage clamp (holding 
potential −60 mV) was performed in the discontinuous mode with a sampling rate of 5–
6.2 kHz. The voltage recordings are acquired using digital/analogue sampling and 
acquisition software. Tetrodotoxin (to block the action potentials), glycine (to enhance 
the NMDA-induced responses) and bicuculline (to block the GABAA receptor 
responses) were routinely included in the aerated Ringer’s solution. In order to 
calculate the effects of the drugs or drug combinations on the prefrontal glutamatergic 
transmission, the recorded amplitude of NMDA- or AMPA-induced currents after 
Olivia Frånberg 
 
36 
administration of a drug or a drug combination was divided by the amplitude of the 
control NMDA- or AMPA-induced current.  
 
The electrophysiological criteria for distinguishing pyramidal from non-pyramidal 
cells have been described previously (Arvanov et al., 1997; Arvanov and Wang, 1998; 
Konradsson et al., 2006). In short, the presumed pyramidal neurons of the mPFC have 
relatively long spike duration (1-3 ms at half maximum spike amplitude) and, in 
addition, show a pronounced spike-frequency adaptation in response to constant-
current depolarization pulses.  
3.9.3 Methodological consideration 
The intracellular single-cell recording technique in vitro enables functional studies 
of the effects of drugs or drug combinations on specific receptor/ion-channels such as 
AMPA and NMDA. The slice technique enables local application of drugs in a 
controlled environment, i.e. both drug concentration and ionic composition outside the 
cells in the slice is controlled.  
 
3.10  Ex vivo receptor binding 
In this ex vivo radioligand binding study, rats were treated by vehicle or risperidone. 
The animals were decapitated 1 h after drug administration. Brains were immediately 
removed from the skull and rapidly frozen in dry-ice cooled 2-methylbutane. Sections 
(20 mm thick) were cut, and thawmounted on microscope slides. The occupancy of 
α2A- and α2C-adrenoceptors by risperidone were measured by ex vivo autoradiography 
using the radioligands [3H]RS79948-197 and [3H]rauwolscine as previously described 
(Marcus et al., 2005). Quantitative autoradiography analysis was performed with the β-
imager according to a standard protocol (Langlois et al., 2001). α2A- and α2C-
adrenoceptor occupancy were measured by quantifying the specific binding of 
[3H]RS79948-197 in the septum and the specific binding of [3H]rauwolscine in the 
STR, respectively. The percentage of receptor occupancy was plotted against dosage 
and the sigmoidal log dose–effect curve of best fit was calculated by nonlinear 
regression analysis. From these dose–response curves, the ED50 (the drug dose 
producing 50% receptor occupancy) were calculated. 
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4 RESULTS AND DISCUSSION 
4.1 Effects of adjunctive α2-adrenoceptor or 5-HT2A receptor 
blockade on the antipsychotic efficacy of low doses of 
risperidone 
The superior clinical efficacy of clozapine has, as previously mentioned, been 
hypothesized to be associated with its potent α2-adrenoceptor and 5-HT2A receptor 
blocking properties in combination with a relatively low D2 receptor occupancy (see 
Introduction). Both α2-adrenoceptor and 5-HT2A receptor antagonists have been shown 
to enhance the effect of typical APDs in treatment-resistant schizophrenia (see 
Introduction). These clinical results are further supported by preclinical studies 
demonstrating that adjunctive blockade of α2-adrenoceptors enhances the antipsychotic-
like effect of low doses of raclopride, a selective D2 receptor antagonist, as well as 
APDs with low α2-adrenoceptor affinity, i.e. haloperidol and olanzapine, and at the 
same time selectively increases prefrontal dopamine release (Hertel et al., 1999a; 
Wadenberg et al., 2007). In addition, an associated facilitation of glutamatergic NMDA 
receptor-mediated transmission in the mPFC of the rat has been observed when 
combining an α2-adrenoceptor antagonist with a D2 antagonist (Marcus et al., 2005). 
Also ritanserin, a 5HT2A/2C receptor antagonist, and M100907, a selective 5-HT2A 
receptor antagonist, have been shown to enhance the effect of raclopride and 
haloperidol, respectively, as regards the antipsychotic-like effect as well as on 
prefrontal dopamine release (Andersson et al., 1995; Liégeois et al., 2002; Wadenberg 
et al., 1998, 2001a). In further support of the role of 5-HT2 receptor blockade, DOI, a 5-
HT2A/2C receptor agonist, has been shown to attenuate clozapine-induced cortical 
dopamine release (Ichikawa et al., 2001a). 
4.1.1 Additional α2-adrenoceptor blockage enhances the risperidone-
induced antipsychotic-like effect and dopaminergic as well as 
glutamatergic NMDA receptor-mediated transmission in the mPFC 
(Paper I) 
The atypical APD risperidone possesses high 5-HT2A receptor affinity but a lower 
affinity for the α2-adenoceptor than clozapine, although still higher than other atypical 
APDs, e.g. olanzapine (Schotte et al., 1996; Shahid et al., 2009). We investigated 
experimentally the ability of adjunctive treatment with the α2-adrenoceptor antagonist 
idazoxan to augment the antipsychotic-like effect of low doses of risperidone using the 
CAR test. The propensity for causing EPS was also assessed, using a catalepsy test. 
The effects of this drug combination on dopamine output in the mesocorticolimbic (i.e. 
mPFC and NAc) terminal regions were measured using in vivo microdialysis in awake 
and freely moving rats. We also investigated the effects of the combination of low 
concentrations of risperidone and idazoxan on NMDA-induced currents in pyramidal 
neurons of the mPFC using intracellular electrophysiological recording. Finally, the 
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α2A- and α2C-adrenoceptor occupancies of risperidone were assessed using ex vivo 
receptor binding.  
 
 
 
Risperidone induced a dose-dependent suppression of CAR, indicating a potent 
antipsychotic-like effect (see Figure 8). The dose of risperidone needed for 
antipsychotic-like effect was between 0.4 and 0.5 mg/kg generating a receptor 
occupancy of approximately 55-70% at D2 receptors (Langlois and te Riele, 2008; 
Wadenberg et al., 2001b) and 12% and 19% at α2A- and α2C-adrenoceptor, respectively. 
Addition of the α2-adrenoceptor antagonist idazoxan (1.5 mg/kg) to a reduced dose of 
risperidone (0.25 mg/kg) enhanced the suppression of CAR, without increasing 
catalepsy (see Figure 9).  
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Effects of risperidone (0.25 mg/kg i.p.) or idazoxan (1.5 mg/kg s.c.), alone and in combination 
with risperidone, on CAR behavior in rats at 20 minutes after administration of vehicle or risperidone. 
The results are presented as median (avoidance %) ± semi-interquartile range. Animals are serving as 
their own control in a change-over design (Li, 1964). ## p<0.01 risperidone vs. vehicle ; ++p<0.01 
idazoxan vs. the combination of idazoxan and risperidone ; ** p<0.01 risperidone vs. the combination of 
idazoxan+risperidone. 
 
Figure 8. Effects of risperidone 
(0.25, 0.3, 0.4, and 0.5 mg/kg i.p.) 
on CAR behavior in rats at 20 and 
after administration of drug. The 
results are presented as median 
(avoidance %) ± semiinterquartile 
range. Animals are serving as their 
own control in a change-over 
design (Li, 1964). ** p<0.01, *** 
p<0.001 for vehicle vs. 
risperidone-treated animals. 
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Both cortical dopamine release and NMDA receptor-mediated responses were 
enhanced (see Figures 10 and 11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. The effects of 10 nM risperidone, 1 µM idazoxan and the combination of risperidone (10 nM) 
+ idazoxan (1µM) on NMDA-induced currents in pyramidal cells of the mPFC. The results are presented 
as mean ± S.E.M. ** p<0.01 between different treatments. For comparison, the maximal effects of 
clozapine (100 nM) and risperidone (20 nM; Konradsson et al., 2006) are included in the figure.  
Figure 10. The effects of risperidone (0.25 mg/kg i.p.) administration on dopamine output in (a) the mPFC and 
(b) the NAc, respectively, in rats pretreated with saline or idazoxan (1.5 mg/kg s.c.). Arrows indicate 
saline/idazoxan and vehicle/risperidone injections. The results are presented as mean ± S.E.M. * p<0.05, ** 
p<0.01, *** p<0.001 compared to vehicle, # p<0.05 risperidone vs. idazoxan+risperidone. 
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The combination of a reduced dose of risperidone (0.25 mg/kg) with idazoxan (1.5 
mg/kg) was estimated to generate approximately 50% D2 receptor occupancy 
(Wadenberg et al., 2001b) and 75% and 90% α2A- and α2C-adrenoceptor occupancy, i.e. 
similar to that of clozapine (Marcus et al., 2005).  
These results propose that the α2:D2 ratio by risperidone is not optimal and that 
additional α2-adrenoceptor blockage may further enhance the antipsychotic effect of 
low doses of risperidone, yet with a low EPS liability. In addition, the augmented 
prefrontal dopamine release and facilitation of glutamatergic NMDA receptor-mediated 
transmission may indicate improvement of both negative symptoms and cognitive 
impairment.  
4.1.2 Additional 5-HT2A receptor blockage does not further enhance the 
antipsychotic-like effect of risperidone (unpublished data) 
We have further investigated the significance of additional 5-HT2A receptor 
blockade to a low dose of risperidone on the antipsychotic-like effect, using the CAR 
test. Adjunct treatment with the selective 5-HT2A receptor antagonist M100907 (0.5 
mg/kg, s.c.) to a suboptimal dose of risperidone (0.25 mg/kg, i.p.) could not further 
enhance the antipsychotic-like effect (see Figure 12). Thus, these results indicate that 
increasing the 5-HT2A:D2 receptor binding ratio of risperidone should not increase its 
antipsychotic efficacy.  
 
 
Figure 12. Effects of risperidone (0.25 mg/kg i.p.) or M100907 (0.5 mg/kg, s.c.), alone and in 
combination with risperidone, on CAR behavior in rats at 20 minutes after administration of vehicle or 
risperidone. The results are presented as median (avoidance %) ± semi-interquartile range. Animals are 
serving as their own control in a change-over design (Li, 1964).  
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4.2 Atypicality of asenapine vs. other antipsychotic drugs 
(Paper II) 
The recently approved APD asenapine was experimentally investigated for its 
antipsychotic-like effect using the CAR test and the propensity for causing EPS using a 
catalepsy test. The effects of asenapine on regional dopamine output in the brain, i.e. in 
the mPFC, the NAc and the STR, were measured using in vivo microdialysis in awake 
and freely moving rats. In vivo voltammetry was used to assess the differential effects 
of asenapine on dopamine output in the core and shell subregions of the NAc. We also 
investigated the effect of asenapine on NMDA-induced currents in pyramidal neurons 
of the mPFC using intracellular electrophysiological recording in vitro.  
 
 
 
 
 
 
The efficacy of asenapine in the CAR test provides significant support for a potent 
antipsychotic action in schizophrenia (see Figure 13). Moreover, the low propensity of 
asenapine to cause catalepsy suggests a low EPS liability (see Table 3). Since asenapine 
displays a marked difference between the dose required for antipsychotic-like action in 
relation to that causing catalepsy, i.e. 2.5 times higher dose required, these preclinical 
findings contribute to define asenapine as a so-called atypical APD. Thus, the results 
are comparable with those obtained with e.g. risperidone (see Paper I). In contrast, for 
haloperidol catalepsy has been found to be near maximal, using a dose inducing a 
comparable suppression of CAR (Wadenberg et al., 2007). In fact, haloperidol has been 
demonstrated to induce marked catalepsy at a dose four times lower than that producing 
a sufficient antipsychotic-like effect. Clozapine on the other hand has not been shown 
to produce any catalepsy, even at very high doses (Wadenberg et al., 1993). Taken 
together, these results, which are supported by clinical studies, thus indicate that 
asenapine, like clozapine and risperidone but in contrast to haloperidol, has an atypical 
profile (Gross and Langer, 1966; Kane et al., 2010; Potkin et al., 2007).  
 
Figure 13. Effects of asenapine on CAR 
behavior in rats 0 to 240 minutes after drug 
administration. +p<0.05 for vehicle- vs. 
asenapine-treated animals. 
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Table 3. Effects of asenapine (0.1, 0.2, 0.5, 1.0 and 2.0 mg/kg, s.c.) on catalepsy in rats.  
 mg/kg Score at 30 min Score at 60 min Score at 120 min 
Asenapine 0.1 
0.2 
0.5 
1.0 
2.0 
< 2 
< 2 
< 2 
2,5 ± 2,1   * 
3 ± 1,2      ** 
<2 
<2 
2 ± 0.6     *** 
3.5 ± 1.5  *** 
2.5 ± 1.1  *** 
< 2 
< 2 
2.5 ± 0.7   ** 
2 ± 1         ** 
3 ± 1.2      ** 
 
The results are shown as median ± semi-interquartile range based on observations of 8 animals per 
treatment group. *p < 0.05, **p < 0.01, ***p< 0.001 saline vs. asenapine treated animals. 
 
Asenapine was shown to markedly enhance the dopamine release in all areas 
studied, i.e. the mPFC, NAc and STR (see Figure 14). The markedly increased 
dopamine efflux in the mPFC produced by asenapine is in similarity with other 
atypical, but not typical, APDs, in particular clozapine (Kuroki et al., 1999; Li et al., 
1998; Moghaddam and Bunney, 1990; Nomikos et al., 1994). Although asenapine was 
shown to enhance the dopamine release not only in the mPFC but also in the STR, no 
associated catalepsy was found, an effect profile that also can be seen with risperidone 
(Hertel et al., 1996). However, clozapine has a preferential effect on the mPFC vs. the 
STR (Hertel et al., 1996). The superiority of atypical compared to typical APDs in 
improving negative and cognitive functions in schizophrenia has been associated with 
the ability to enhance prefrontal dopamine (c.f. Introduction).  
 
Figure 14. Effects of asenapine administration on dopamine output in mPFC, NAc and STR. Each point 
represent the mean ± S.E.M. 
 
Moreover, the preferential effect of low doses of asenapine on dopamine output in 
the shell vs. the core subregion of the NAc also resembles that of atypical, in particular 
clozapine, but not typical APDs, such as haloperidol (see Figure 15; Marcus et al., 
1996, 2000), further supporting the atypical profile of asenapine.  
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Figure 15. Over all effects of asenapine on extracellular dopamine in the shell and the core of the NAc. 
Data are represented as mean ± S.E.M. The dotted line represents the baseline value (100%). +p<0.05, 
++p<0.01 shell or core vs. baseline. *p<0.05 shell vs. core. 
Finally, in similarity with risperidone and clozapine (20 and 100 nM, respectively; 
Konradsson et al., 2006), asenapine, however at a considerably lower concentration (5 
nM), potentiated the NMDA-induced responses in pyramidal cells of the mPFC (see 
Figure 16). The maximal facilitation was similar to that of risperidone, but lower than 
that of clozapine. These results are in line with previous observations showing that 
atypical but not typical APDs facilitate NMDA-induced currents in the pyramidal cells 
of the mPFC (Ninan et al., 2003a). In a consecutive study, the facilitation of these 
glutamatergic NMDA-induced currents in pyramidal cells of the mPFC induced by 
asenapine was found to be mediated by prefrontal dopamine and executed via D1 
receptors (Jardemark et al., 2010), an effect that suggests improvement of cognitive 
functioning (c.f. Introduction). Asenapine, in similarity with clozapine and olanzapine 
but not haloperidol (Ninan et al., 2003b), was furthermore found to reverse the PCP-
induced blockade of cortical NMDA-induced currents in pyramidal cells, confirming a 
cognitive improving effect of asenapine (Jardemark et al., 2010). This conclusion is 
directly supported by behavioral studies demonstrating reversal of PCP-induced 
cognitive impairment by asenapine, an effect shown to be mediated via D1 receptors 
(Elsworth et al., 2012; Snigdha et al., 2011).  
 
 
 
Figure 16. A bar graph illustrating the maximal effect 
of asenapine vs. clozapine and risperidone (see 
Konradsson et al., 2006) on NMDA-induced currents 
in the mPFC of the rat. +p<0.05, ++p<0.01, +++p<0.001 
vs. control NMDA-induced currents. *p<0.05 as 
indicated in the figure. 
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    Taken together, our results provide new insights in the mechanism of action of the 
novel APD asenapine, which thus was found to display an atypical profile. Our data 
specifically suggest that asenapine may exhibit a potent antipsychotic activity in spite 
of a very low EPS liability. Its ability to increase both dopaminergic and glutamatergic 
transmission in rat mPFC suggests that asenapine may have an advantageous effect not 
only on positive symptoms in patients with schizophrenia, but also on negative and 
cognitive symptoms.  
 
4.3 Effects of asenapine on cortical monoamine output in 
brain. Differential effects on cortical and subcortical 
release of dopamine (Paper III) 
Using single-cell recording techniques, we here examined the effects of systemic 
asenapine on the firing activity of mesocorticolimbic dopaminergic neurons in the VTA 
and noradrenergic neurons in the LC. Furthermore, using in vivo microdialysis, we 
investigated the effects of systemic administration of asenapine on cortical 
noradrenaline and serotonin output. We also studied the effects of local administration 
of asenapine, using reverse dialysis, on cortical dopamine, noradrenaline and serotonin 
output and dopamine output in the NAc. Finally, we used application of TTX into the 
VTA, which blocks neuronal activity in dopamine neurons, to further analyze the mode 
of action of asenapine in the mPFC vs. the NAc. 
Intravenous asenapine dose-dependently increased both dopaminergic and 
noradrenergic neuronal firing (see Figures 17 and 18). 
 
 
Figure 17. Effects of cumulative doses of asenapine 0-0.2 mg/kg, i.v. (a, b) on the firing pattern of 
dopamine cells in the VTA in anesthetized rats. a) Firing rate for each cell is represented by a circle, and 
mean ± SEM are indicated by horizontal lines. b) Δ Burst firing for each cell is represented by a triangle, 
and median is indicated by a horizontal line. *p<0.05, **p<0.01 compared with saline. 
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In similarity with its effects on accumbal and cortical dopamine (see above), 
asenapine also increased cortical noradrenaline and serotonin output following systemic 
administration (see Figure 19).  
 
Figure 19. Overall effects of systemic administration of asenapine (0.05, 0.1, and 0.2 mg/kg, s.c.) on a) 
noradrenaline output in the mPFC and b) serotonin output in the FC in awake, freely moving rats. Bars 
represent mean ± SEM percent of baseline level over 150 min following asenapine administration. The 
dotted line represents the baseline value (100%). ++p<0.01, +++p<0.001 saline vs. asenapine treated 
animals. **p<0.01 between treatment groups.  
 
 
 
 
 
 
 
 
 
Figure 18. Effects of cumulative 
doses of asenapine (0-0.05 mg/kg, 
i.v.; n=6-7) on firing rate of 
noradrenaline cells in the LC in 
anesthetized rats. Firing rate for each 
cell is represented by a circle, and 
mean ± SEM are indicated by 
horizontal lines. *p<0.05, **p<0.01 
compared with saline. 
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Local administration of asenapine did not affect dopamine output in the NAc, but still 
increased cortical dopamine, noradrenaline, and serotonin output (see Figure 20).  
 
Figure 20. Effects of local infusion of asenapine (10, 100, and 1000 μM) on a) dopamine output in the 
NAc, b) dopamine output in the mPFC, c) noradrenaline output in the mPFC, and d) serotonin output in 
the FC. Each bar represents mean ± SEM percent of baseline level over 60 min following asenapine 
infusion. The dotted line represents the baseline value (100%). +p<0.05, ++p<0.01, +++p<0.001 each 
concentration vs. baseline level. *p<0.05, **p<0.01, ***p<0.001 between different concentrations. 
 
TTX perfusion into the VTA blocked accumbal but only partially prefrontal cortical 
dopamine outflow induced by systemic administration of asenapine (see Figure 21).  
 
Figure 21. Effects of TTX (1.0 μM) perfusion of the VTA and concomitant systemic administration of 
asenapine (0.2 mg/kg, s.c.) on extracellular a) dopamine concentrations in the NAc and b) dopamine 
output in the mPFC. Horizontal bar indicates TTX infusion, and arrow indicates asenapine 
administration, respectively. Each point represents the mean ± SEM percent of baseline. The dotted line 
represents the baseline value (100%). +p<0.05, ++p<0.01 compared to baseline level. #p<0.05, ##p<0.01, 
###p<0.001 compared with sample immediately preceding the injection of asenapine. 
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Our results propose that, whereas the increased dopamine outflow in the NAc caused 
by systemic asenapine is dependent on, and mediated by, the increased dopamine 
neuronal activity, the facilitation of prefrontal dopamine outflow by asenapine is 
largely independent on nerve impulse activity and instead depends on a local action at 
the nerve terminal level. This conclusion is supported by the finding that after intra-
VTA application of TTX a markedly reduced dopamine outflow in the NAc but only 
partially reduced dopamine outflow in the mPFC was seen, and that TTX essentially 
abolished the effect of systemic asenapine on dopamine efflux in the NAc but not in the 
mPFC. Moreover, locally administered asenapine increased dopamine outflow in the 
mPFC, but had no significant effect in the NAc, which further supports this conclusion. 
In view of the high affinity of asenapine for 5-HT2A/2C receptors and α2-adrenoceptors 
(Schotte et al., 1996; Shahid et al., 2009), as well as the effects of selective ligands for 
these receptors on dopamine release in the PFC vs. the NAc (Hertel et al., 1999a,b; 
Ichikawa et al., 2001b; Liégeois et al., 2002), antagonist activity at these receptors 
seems likely to contribute to the increased prefrontal dopamine outflow induced by 
asenapine. These mechanisms may also help explain the concomitantly increased 
prefrontal noradrenaline outflow and, to some extent, the increase in cortical serotonin 
output. The finding that asenapine augments the availability of both cortical 
noradrenaline and serotonin, which represent effects shared by a range of 
antidepressant drugs, furthermore supports its utility for the treatment of depressive 
and/or negative symptoms in schizophrenia as well as depression as such.  
Taken together, these data and our previous work demonstrate a specific 
pharmacologic profile of asenapine, as well as some of its similarities with clozapine, 
especially with regard to its effects in the PFC, which may have bearing on its cognitive 
enhancing effects. As impairment of working memory often represents a major 
symptom not only in schizophrenia and bipolar disorder, but also in MDD, the potential 
utility of low dose asenapine in the treatment of MDD is further supported. 
Additionally, our results from the electrophysiological experiments in vivo, showing 
that very low doses of asenapine may enhance the excitability of the reward-related 
dopaminergic neurons in the VTA, substantiate this contention. The data which show 
that very low doses of asenapine also stimulates the firing of brain noradrenergic 
neurons in the LC, an effect shared by certain antidepressant drugs, such as mianserin 
(Engberg and Svensson, 1980), provide further evidence in this direction. 
 
4.4 Effects of asenapine on cortical monoamine output; role 
of 5-HT2A receptor- and α2-adrenoceptor-mediated 
mechanisms (Paper IV) 
The potential role of α2-adrenoceptor and 5-HT2A receptor blockage in the effects of 
e.g. risperidone and clozapine has previously been discussed. Notably, asenapine 
exhibits high affinity for 5-HT2A receptors and α2-adrenoceptors (see section 1.11). 
Since our previous data indicate that the monoaminergic release by asenapine may to a 
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significant extent be mediated via local mechanisms in the mPFC, we here specifically 
investigated the role of local 5-HT2A receptors and α2-adrenoceptors for these effects. 
Reverse microdialysis in vivo with local application into the mPFC of selective receptor 
ligands were used. 
Intracortical administration of DOI, a selective 5-HT2A receptor agonist, increased 
the monoamine output in the mPFC, effects that were reversed by concomitant 
administration of the selective 5-HT2A receptor antagonist M100907 or asenapine (see 
Figure 22). These results indicate a potent 5-HT2A receptor affinity by asenapine in vivo 
as well as an involvement of 5-HT2A receptors in the regulation of the monoamine 
release of asenapine.  
 
 
Figure 22. The 5-HT2A antagonistic effect of asenapine on extracellular concentration of a) dopamine, b) 
noradrenaline and c) serotonin output in the mPFC. The mean transmitter release during DOI infusion, 
that is, 61–120 min. Data are presented as % of baseline (mean ± SEM). *p < 0.05, **p < 0.01, and ***p 
< 0.001 comparisons vs. DOI infusion alone. 
 
Intracortical administration of the selective α2-adrenoceptor agonist clonidine 
significantly decreased the monoamine release in the mPFC (see Figure 23). 
Application of the α2-adrenoceptor antagonist idazoxan blocked the clonidine-induced 
reduction of dopamine and noradrenaline release. However, the effect on serotonin was 
less pronounced. Simultaneous infusion of asenapine did not acutely block the 
clonidine-induced decrease in transmitter release. However, following termination of 
the clonidine infusion the transmitter release remained at a low level. During this 
interval, i.e. the following hour after the clonidine infusion, intracortical infusion of 
asenapine restored the catecholamine release to baseline level, indicating an α2-
adrenoceptor blocking effect of asenapine which was somewhat delayed. When given 
alone, the infusion of asenapine, M100907 or idazoxan, in the concentrations used, did 
not affect monoamine release. 
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In summary, these findings demonstrate that asenapine possesses an antagonistic 
affinity for local 5-HT2A and α2-adrenergic receptors at the nerve terminals in the 
mPFC. Thus, 5-HT2A receptor antagonism and α2-adrenoceptor blockage induced by 
asenapine in the mPFC may contribute to enhance prefrontal monoamine release in 
vivo and, secondarily, to its effect on positive and negative symptoms as well as pro-
cognitive and antidepressant profile. 
Figure 23. The α2-
antagonistic effect of 
asenapine on extracellular 
concentration of    
a–b) dopamine,  
c-d) noradrenaline, and   
e-f) serotonin output in 
the mPFC. a, c, e) The 
mean transmitter release 
during clonidine infusion, 
that is, 61–120 min. b, d, 
f) The mean transmitter 
release after clonidine 
infusion was completed, 
that is, 121–180 min. Data 
are presented as % of 
baseline (mean ± SEM).  
*p< 0.05, **p< 0.01, and 
***p< 0.001 comparisons 
vs. clonidine infusion 
alone. 
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4.5 Adjunctive treatment with asenapine augments the 
escitalopram-induced effects on monoaminergic and 
glutamatergic NMDA as well as AMPA receptor-mediated 
transmission in the medial prefrontal cortex. (Paper V) 
In recent years, the beneficial effects of low to moderate doses of atypical APDs as 
add-on to SSRIs in the management of treatment-resistant depressive symptoms in 
MDD as well as bipolar disorder, which may generate an enhanced antidepressant 
effect with a faster onset of action, have been increasingly supported (see section 1.3.4 
and 1.4.4). According to previous studies, the mechanism for this augmentation 
strategy may involve activation of cortical catecholamine output (Dremencov et al., 
2007; Koch et al., 2004; Marcus et al., 2012; Zhang et al., 2000). In addition, an 
associated facilitation of glutamatergic NMDA receptor-mediated transmission in 
pyramidal cells of the mPFC, has been observed (Marcus et al., 2012). Recently, the 
very rapid and potent antidepressant action of the NMDA receptor antagonist ketamine 
as well as scopolamine has been shown to be dependent on activation of prefrontal 
AMPA receptors (Duman, 2011; Li et al., 2010).  
We here investigated whether the atypical APD asenapine may further enhance the 
effect of the SSRI escitalopram on monoamine availability in the mPFC as well as 
dopamine availability in the NAc, using in vivo microdialysis in freely moving rats. To 
study the glutamatergic NMDA- and AMPA-induced currents of pyramidal neurons of 
the mPFC, intracellular electrophysiological recording in vitro was used.  
Low doses of asenapine (0.05 and 0.1 mg/kg) as add-on to escitalopram were found 
to significantly increase the availability of monoamines in the mPFC (see Figure 24 a-
c). In the NAc, escitalopram increased the extracellular levels of dopamine, which were 
further enhanced by adjunctive asenapine (see Figure 24 d).  
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Figure 24. The effects of escitalopram 
(5 mg/kg, s.c.), asenapine (0.1 mg/kg, 
s.c.) alone and the combination of 
escitalopram and asenapine on  
a) dopamine, b) noradrenaline and  
c) serotonin output in the mPFC, and 
d) dopamine output in the NAc. 
Effects calculated as mean transmitter 
output during 60-240 min for mPFC 
and 45-240 for NAc, i.e. after the 
second injection. The dotted line 
represents baseline (100%). The 
results are presented as mean ± SEM. 
*p<0.05, **p<0.01, ***p<0.001 vs. 
control, i.e. saline + saline. ##p<0.01, 
###p<0.001 as indicated in the 
figures. 
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Moreover, the combination of asenapine and escitalopram in low concentrations, 
which had no effects when given alone, was found to facilitate both NMDA- and 
AMPA-induced currents in pyramidal cells of the mPFC (see Figure 25). Recent data 
indicate that also the combination of olanzapine and fluoxetine, in concentrations that 
were without effect when given alone, facilitates AMPA-induced currents (Björkholm 
et al., 2012). As this drug combination is known to improve depressive symptoms with 
a fast onset in both bipolar disorder and treatment-resistant MDD (Dubé et al., 2007; 
Nelson and Papakostas, 2009; Shelton et al., 2005), our data suggest that a similar 
clinical outcome with a combination of asenapine and an SSRI would be expected. 
 
 
Figure 25. Effects on a) NMDA- and b) AMPA-induced currents in pyramidal cells of the rat mPFC of a 
combination of asenapine and escitalopram at 30 min after drug application. The results are presented as 
mean ± SEM. *p<0.05 vs. control NMDA-induced currents. ##p<0.01 as indicated in the figure. The 
holding potential was -60 mV. 
 
Our results generally support the notion that the effects of adjunctive treatment of 
atypical APDs to SSRIs in treatment-resistant MDD may be related to an increase of 
prefrontal catecholaminergic output. The enhanced prefrontal monoamine release and 
the concomitant facilitation of NMDA-induced currents in the mPFC provide a 
rationale for potential pro-cognitive as well as enhanced antidepressant effects of the 
combination of asenapine and escitalopram. Finally, our novel observation 
demonstrates that this drug combination, as previously shown with ketamine and 
scopolamine, also markedly facilitates AMPA receptor-mediated responses in the 
mPFC of the rat. This effect may thus contribute to explain the potent and rapidly 
enhanced antidepressant effect that has been seen clinically following add-on treatment 
of atypical APDs with SSRIs in treatment-resistant depression (see section 1.3.4 and 
1.4.4). Needless to say, further studies are needed to validate this notion. 
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5 SUMMARY AND CONCLUDING REMARKS  
In the present set of experimental studies we demonstrate that additional blockage of 
α2-adrenoceptors, but not 5-HT2A receptors, may further enhance the antipsychotic-like 
effect of low doses of risperidone without increasing EPS liability. These behavioral 
changes were accompanied by an increase in prefrontal dopaminergic and 
glutamatergic NMDA receptor-mediated transmission. 
Subsequently, asenapine was shown to possess a potent antipsychotic-like effect 
without any associated high risk of EPS and like other atypical, but not typical APDs 
asenapine was shown to markedly increase cortical dopamine release as well as 
facilitate glutamatergic NMDA receptor-mediated transmission in pyramidal cells in 
the mPFC. In similarity with other atypical APDs, asenapine also preferentially 
increased dopamine release in the shell relative to the core subregion of the NAc. 
Furthermore, whereas the dopamine release induced by asenapine in the NAc was 
dependent on the concomitant stimulation of neuronal firing in the dopamine neurons 
originating in the VTA, the cortical dopamine release was largely regulated via local 
mechanisms in the nerve terminal region. When further investigating the effects of 
asenapine, we found that this drug also augments the release of noradrenaline and 
serotonin. Moreover, asenapine was shown to exert a potent antagonistic activity at α2-
adrenergic and 5-HT2A receptors in vivo, an effect found to be involved in its regulation 
of cortical monoamine release. 
Finally, our data demonstrate that add-on treatment with asenapine in combination 
with the SSRI escitalopram enhances the monoamine output in the mPFC. Moreover, 
the combination of asenapine and escitalopram, in concentrations that had no effects 
when given alone, was found to facilitate both glutamatergic NMDA- as well as 
AMPA-mediated responses in the pyramidal cells of the mPFC, supporting a clinical 
utility of asenapine as adjunctive treatment in depressive disorders. 
Taken together, these studies contribute to establish asenapine as an atypical APD 
and help explain, at the neurobiological systems level in the brain, some of the clinical 
characteristics and utilities of the drug. The data also support a cognitive enhancing 
effect of asenapine, as well as an antidepressant potential, which in view of the 
structural similarities between asenapine and mianserin and mirtazapine is not 
surprising per se. Although asenapine like most atypical APDs is a potent 5-HT2 
receptor antagonist, this part of its pharmacological profile can obviously not serve to 
differentiate asenapine from other atypical APDs. Rather, its high affinity to a number 
of serotonergic receptors may be of importance in this regard. Given a substantial set of 
studies, both clinical and preclinical, the α2-adrenoceptor antagonistic effect of 
asenapine may underlie some of its apparently rather broad clinical utility. A recent 
meta-analysis (Hecht and Landy, 2012) provides substantial support for this view, in 
particular as regards its effects on negative symptoms and cognitive impairment in 
schizophrenia. Since a previous clinical study in patients with MDD (Sanacora et al., 
2004) reported that addition of an α2-adrenoceptor antagonist to fluoxetine seemed to 
both increase the number of responders and hasten the antidepressant response, the α2 
receptor antagonistic action of asenapine may not only contribute to augment the 
antidepressant action of SSRIs, but also reduce the time to onset of the effect. This 
notion has recently been supported by studies of early changes in neuroplasticity-
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related genes following chronic antidepressant treatment (Serres et al., 2012), where a 
combined α2-adrenoceptor antagonist/SNRI generated a more rapid response than a 
potent SNRI without α2-adrenoceptor blocking action i.e. venlafaxine. 
Our novel observation that a combination of asenapine and an SSRI, escitalopram, 
just like the rapidly acting antidepressants ketamine and scopolamine, may facilitate 
AMPA receptor-induced responses in the mPFC, provides further support for an 
antidepressant potential of asenapine as adjunctive treatment in MDD. Moreover, 
previous experimental data have shown a dose-dependent antidepressant effect of an 
AMPA-receptor potentiatior that during subchronic treatment for three weeks was 
comparable to that of fluoxetine, but showed a clearly faster onset of action, i.e. 
appearing within one week vs. two weeks, respectively (Knapp et al., 2002). Thus, both 
α2-receptor antagonism and AMPA receptor potentiation support the utility of 
asenapine as adjunct treatment to SSRIs in MDD as well as in bipolar depression. 
Although presently a multitude of APDs are available, more treatment options are 
obviously needed, both for reasons of efficacy and side effect profile. In view of the 
partial overlap in symptoms and to some extent even underlying neurobiology between 
schizophrenia, bipolar disorder and MDD, drugs with a broad clinical utility may be of 
particular interest. This notion is further supported by the recently reported marked 
reduction of suicide risk following combined antipsychotic and antidepressant 
medication in schizophrenia (Tiihonen et al., 2012). Finally, by inference our data also 
suggest that increasing the α2:5-HT2A receptor binding ratio of risperidone might serve 
to increase its utility as adjunct treatment in MDD and, like e.g. clozapine, reduce 
suicide risk in the treatment of schizophrenia. 
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